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1. NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT): 
A PLEIOTROPIC ENZYME 
 
Nicotinamide phosphoribosyltransferase (NAMPT) is a pleiotropic protein that 
exists in two distinct forms: (i) an intracellular form (iNAMPT) and (ii) an 
extracellular form (eNAMPT) 1.  
	
	
Figure 1. The role of sub-cellularly localized NAMPT in NAD synthesis. QAPRT, 
quinolinic acid phosphoribosyltransferase; NAPRT, nicotinic acid phosphoribosyltransferase; 
NRK, nicotinamide riboside kinase; NMNAT, NMN adenylyltransferase. NAD metabolites or 
substrates: Trp, tryptophan; NA, nicotinic acid; NAR, nicotinic acid riboside; NR, 
nicotinamide riboside; Nam, nicotinamide; QA, quinolinic acid2. 
	
1.1 iNAMPT: role in NAD metabolism 
 
NAD is one of the most important cofactors in cellular metabolism and its main 
role is in redox reactions, transferring electrons from a reaction to another.  The 
NAD synthesis starts from different precursors: L-triptophan (Trp), 
nicotinamide (NAM, vitamin B3), nicotinic acid (NA, vitamin B3), 
nicotinamide riboside (NR) and the recently described nicotinic acid riboside 
(NAR) (Figure 1). While lower eukaryotes and prokaryotes use the nicotinic 
acid pathway as a major source of NAD synthesis, in humans the main source 
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of cellular NAD is the uptake of NA, NAM, and NR from the diet or the reuse 
of NAM released intracellularly after consumption by NAD-utilizing enzymes, 
in the so-called NAD salvage pathway.  
The intracellular form of NAMPT is a homodimeric class type II 
phosphoribosyltransferase, which represents the rate-limiting enzyme in this 
pathway. In detail, iNAMPT catalyzes the production of nicotinamide 
mononucleotide (NMN) through the condensation of nicotinamide (NAM) 
with 5-phophoribosyl-1-pirophosphate (PRPP) and ATP; afterwards, NMN is 
converted to NAD by nicotinamide mononucleotide adenylyltransferase 
(NMNAT).  
Since NAD covers an important role in cells and iNAMPT regulates the 
production of NAD, it is clear that iNAMPT is a key enzyme in cellular 
energetics and cellular survival. Moreover, iNAMPT, affecting the 
intracellular levels of NAD, indirectly modulates the action of many NAD-
dependent enzymes, such as Poly (ADP-ribose) polymerases (PARPs) and 
sirtuins (SIRTs), which explicate some of their functions in DNA damage and 
in the regulation of gene transcription3, 4. It is therefore not surprising that 
iNAMPT has been shown to be up-regulated in several disorders and has been 
considered a druggable target. 
Structurally, NAMPT is a protein consisting of 491 amino acids with a 
molecular weight of 55 kDa. From the crystallographic structure, iNAMPT 
results in a dimeric form, and the interface of the two monomers serves as a 
pocket that accommodates NMN5. Different selective inhibitors have been 
designed, such as FK866 and CHS828, which compete with NMN for the 
catalytic site. These inhibitors entered into phase I/II clinical trials for non-
solid and solid tumours; unfortunately, up to date there is no information about 
their efficacy in vivo. Recently, preclinical characterization of second-
generation inhibitors have unmasked retinopathy and cardio-toxicity as 
potential side effects of these class of compounds6.  
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1.2 eNAMPT: role as cytokine 
 
NAMPT is not only an enzyme involved in metabolism, but it has been shown 
that this protein may be secreted through a non-classical pathway. For 
simplicity, I will refer to this form as extracellular NAMPT (eNAMPT) 
throughout my thesis.  
Samal et al. described for the first time eNAMPT as an active cytokine in the 
extracellular space in 19947. They reported its secretion from pre-B cells and 
its ability to synergize with stem cell factor and IL-7 to promote colony 
formation7. At the time, given that the identity with iNAMPT had not been 
recognized yet, eNAMPT was referred to as pre-B-cell colony-enhancing 
factor 1 (PBEF1).  
This paved the way to its classification as a cytokine. Since then, a number of 
reports have strengthened its biological potential as a paracrine and autocrine 
factor. In 2005, once again its name was modified to “visfatin” because it was 
thought to be secreted preferentially by visceral adipose tissue in obese 
patients8, 9. Now, it is clear that eNAMPT is not only produced by pre-B cells 
and adipocytes but also readily detectable in conditioned media from cultures 
of most cell types (Table 1)2. Immune cells, such as macrophages and 
leucocytes, neurons and glia cells, cardiomyocytes, melanocytes and 
fibroblasts have been demonstrated to release eNAMPT in the extracellular 
space under basal conditions or under stimulation.  
Few studies have focused the attention on the type of stimuli that might induce 
eNAMPT release from cells. First, it is clear that eNAMPT release occurs in 
the absence of cell death and therefore appears to be a true and specific 
phenomenon. Stress conditions, including ischaemia10 and oxygen–glucose 
deprivation (OGD), strongly increase eNAMPT release in neurons and glial 
cells11, and hypoxia has been shown to be a triggering stimulus in melanoma 
cells12.  
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All these stress conditions appear to be highly relevant in cancer as nutrient 
deprivation, hypoxia and oxidative stress are all features of the tumour micro-
environment.  
 
Table 1. Summary of cell types that release eNAMPT2. 
 
Only recently, it has been demonstrated that eNAMPT can be released by most 
if not all cancer cell lines. Interestingly, conditioned media from tumoural cells 
appears to contain substantially more eNAMPT when compared with non-
tumoural cultures. However, this parallels with the over-expression of 
intracellular NAMPT reported in the majority of cancer cell lines and tumour 
tissues13, 14.  
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Nutritional changes have also been shown to promote eNAMPT release. 
Indeed, other than the first evidence which linked increased eNAMPT levels 
to obesity-linked diabetes8, secretion of eNAMPT promoted by glucose or high 
insulin has been reproduced by others15, 16. Last, eNAMPT, like many other 
cytokines, is also secreted in response to inflammatory stimuli, such as LPS 
and ATP in monocytes17.  
Overall, a wide range of stimuli has been used to modulate eNAMPT release 
and this may indicate that eNAMPT secretion is recruited to function under 
specific circumstances.  
 
2. eNAMPT and disease: autocrine and paracrine effects 
The secretion of eNAMPT by different cell types suggests that this cytokine 
has pleiotropic roles in physiology and pathology and it is not surprising that 
circulating eNAMPT levels are frequently increased/deregulated in patients 
affected by different metabolic and inflammatory disorders, including cancer.  
In Figure 2 the main findings on the roles of eNAMPT in cells are summarized.  
 
Figure 2. Autocrine and paracrine effects of eNAMPT2. 
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2.1 eNAMPT: metabolic disorders  
 
As described previously, Fukuhara et al. described for the first time that 
eNAMPT has an insulin-mimetic activity. Indeed, they demonstrated that 
eNAMPT exerted insulin-mimetic effects in cultured cells and lowered plasma 
glucose levels in mice. Furthermore, the administration of recombinant 
eNAMPT on adipocytes and β cells induces their proliferation and protects 
them from apoptosis8, 18. They suggested that these effects are mediated by the 
binding of eNAMPT to the insulin receptor, this article was retracted, since 
other groups were unable to demonstrate the binding of eNAMPT to the insulin 
receptor 19. 
Since then, numerous reports have analysed the correlation between plasma 
eNAMPT levels and metabolic disorders. For example, Revollo et al. 
demonstrated that eNAMPT, partially thought NAD biosynthesis, plays a 
critical role in the regulation of glucose-stimulated insulin secretion (GSIS) in 
pancreatic β cells, but it does not possess insulin-like activity19. Indeed, they 
demonstrated that NAMPT through NAD biosynthesis regulates insulin 
secretion, but they failed to reproduce the insulin-mimetic effects using 
different recombinant eNAMPT obtained from different species (prokaryotic 
and eukaryotic). 
On the contrary, Xie H et al., reported in osteoblasts an insulin-like action of 
eNAMPT20, indeed after eNAMPT treatment they observe an increased 
glucose uptake, proliferation and type I collagenase production. Similarly, 
Song HK et al. showed that eNAMPT treatment of kidney mesangial cells 
increases the uptake of glucose, GLUT-1 protein expression, and synthesis of 
pro-fibrotic molecules. In addition, they observed that eNAMPT is able to 
reduce the plasma glucose levels in mice21. 
Importantly, correlates to human diseases have also been found. Many research 
groups observed a possible correlation with circulating eNAMPT levels and 
the anthropometric and metabolic parameters in patients affected by diabetes 
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type II.  Moreover, Berndt et al., found a correlation between circulating 
eNAMPT levels and obesity, BMI (Body Mass Index) and body fat, but not 
with the size of the circumference of the waistline and with the WHR (Waist-
hip Ratio)22. On the contrary, other researcher groups obtained opposite results 
regarding the correlation of plasma eNAMPT levels and metabolic disorders. 
These conflicting results might be explained by the variability in the 
commercial immunoassays available for the detection of eNAMPT. For 
example, Körner et al. identified an unknown protein (with high molecular 
weight of eNAMPT) that compromised the measurement of eNAMPT in one 
of the commercial immunoassay kits24.  
 
2.2 eNAMPT: inflammatory diseases   
 
Many evidences have been provided for an involvement of eNAMPT in both 
the innate and adaptive immunity. First, eNAMPT is secreted upon 
inflammatory stimuli (listed in Table 1). For example, Jia et al. demonstrated 
that the amount of eNAMPT is increased in the presence of different 
inflammatory stimuli such as LPS, IL-1β and TNF-α in monocytes and 
neutrophils in vitro25.  
Not only, but the stimulation of innate and adaptive immune cells with 
eNAMPT is able per se to induce an inflammatory response, inducing a 
positive loop. Indeed, it has been reported that eNAMPT induces M2 
polarization, increases phagocytosis and promotes macrophage survival and 
myeloid differentiation26. Moreover, eNAMPT treatment induces the 
activation of T cells and B cells. In this direction, different studies reported that 
eNAMPT treatment increased the mRNA levels and the release of different 
cytokine such as IL-1β, IL-1Rα, IL-10, IL-6, IL8 and TNF-alpha through the 
activation of p38, ERk1/2, AKT, JNK, NF-κB or the JAK/STAT3 pathways2, 
27-29. Moreover, eNAMPT induces the expression of iNOS (inducible NO-
synthase), which leads to the formation of peroxynitrite in macrophages30. 
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It has been demonstrated also that the injection of eNAMPT in peritoneal mice 
stimulates the production of pro-inflammatory cytokines from mononuclear 
blood cells (such as IL-8 and IL-16) and increases mRNA expression and 
plasma levels of IL-631.  
All these data support the evidence that eNAMPT plays a crucial role in 
inflammation. Likewise, eNAMPT circulating levels are up-regulated in 
different acute and chronic inflammatory conditions, such as lung injury, 
atherosclerosis, ulcerative colitis, rheumatoid arthritis, psoriasis and sepsis. 
Rheumatoid arthritis. High levels of eNAMPT in plasma are associated with 
the severity of joint damage, prompting cartilage erosion32. Moreover, 
eNAMPT regulates the production of PGE2, MMP-3 and ADAMTS synthesis 
in chondrocytes, postulated as a degradation marker in patients33, 34.  
Acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). 
It has been reported that eNAMPT is one of the proteins overexpressed in ALI 
and ARDS, determining increased levels of the cytokines such as IL-1β, TNF-
α and IL-8. Moreover, in heterozygous NAMPT+/- mice, operating with a 
deletion of a single allele, there is a modest protection from lung injury35.  
Inflammatory bowel disease. Several studies have reported the correlation 
between high plasma levels of eNAMPT and ulcerative colitis and Chron’s 
disease and there is a correlation with the stage of the disease. Due to the 
anatomic proximity of bowel and visceral fat, the bowel inflammation could 
activate adipocytes, which release several cytokines and adipokines, among 
which eNAMPT. Interestingly, after three months of treatment, eNAMPT 
levels were significantly reduced36.  
 
2.3 eNAMPT: cancer 
The role of iNAMPT in the cancer pathology is well documented 13, 14, 37. 
Indeed, iNAMPT has been observed overexpressed in cancer cells, and the 
treatment of tumoural cells with FK866 leads to cellular death in vitro13. Also 
in tumour-bearing mice, the treatment with FK866/CHS828 leads to reduction 
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in tumour volume and metastasis formation compared to controls. As described 
above, FK866/CHS828 entered phase I/II clinical trials for non-solid and solid 
tumour (www.clinicaltrials.gov). 
To date, it is known that also eNAMPT has a pivotal role in cancer. Indeed, as 
observed for other cell types, eNAMPT has a cytokine effect on tumour cells 
and controls several cancer hallmarks.  
Indeed, the treatment of eNAMPT on different tumour cells, such as PC3 
(prostate cancer) cells, melanoma cells and MCF7 (breast cancer) cells, results 
in a proliferative effect28, 29. Indeed, it has been demonstrated that the eNAMPT 
treatment on cancer cells increases mRNA levels of VEGF, MMP-2/9, 
CXCL12 and CXCR4/7 thought the activation of MAPK, NF-κB and notch 
pathways38-41.  All these effects are then translated in an increase in 
proliferation, migration and colony formation.    
Furthermore, eNAMPT seems to promote the epithelial-mesenchymal 
transition (EMT), a process in which epithelial cells lose their adhesion 
properties and become mesenchymal stem cells with migratory and invasive 
properties. Regarding this aspect, Cheng et al. and Soncini et al. have shown 
that eNAMPT, in a NF-κB- dependent manner, promotes osteosarcoma and 
breast cancer cell migration through the reduction of E-cadherin expression 
and the increase of N-cadherin, vimentin and ZEB142, 43.  
The tumoural microenvironment is a heterogeneous environment in which 
tumoural cells cooperate with immune cells, bone marrow-derived 
inflammatory cells, endothelial cells and fibroblasts. It is evident that 
eNAMPT may affect cell types other that tumoural cells in vivo. 
In endothelial cells, eNAMPT treatment induces the activation of MAPK, 
PI3K, AKT and NF-κB intracellular pathways, which results in the increase of 
the release of Fibroblast Growth Factor 2 (FGF-2), Vascular-Endothelial 
Growth Factor (VEGF) and nitric oxide (NO)44. Kim et al. and Adya et al. 
reported that eNAMPT treatment of human umbilical vein endothelial cells 
(HUVECs) promotes angiogenesis through the activation of ERK1/2. Indeed, 
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in vivo and in vitro, it has been found that eNAMPT stimulates the formation 
of new vessels, facilitating the migration and formation of veins in HUVECs. 
This action is attributable to both the up-regulation of VEGF and of the matrix 
metalloproteases (MMP) and the suppression of metallopeptidase inhibitor 1-
2 (TIMP 1-2). Moreover, the inhibition of PI3K/Akt and ERK1/2 leads to a 
drastic decrease in the effect of eNAMPT on the activation of the gene 
expression of VEGF and MMP, and consequently leads to a reduction of 
endothelium proliferation and capillary formation45-48. In vivo, Kim et al. 
observed that eNAMPT in matrigel plug assays and in chorioallantoic 
membrane assay in mice promotes angiogenesis29, 46. The pro-angiogenetic 
effects of eNAMPT observed on HUVECs are also reflected on cancer cells.  
Moreover, Audrito et al. have shown that eNAMPT is able to polarize resting 
monocytes obtained from chronic lymphocytic leukaemia towards M2-
macrophages with tumour-supporting properties26. Indeed, eNAMPT 
treatment increased CD163, CD206 expression and the release of IL-6 and IL-
8 tumour-promoting cytokine and IL-10 immunosuppressive cytokine. 
Therefore, eNAMPT may modulate cancer cell proliferation and migration but 
also angiogenesis and tumour-related inflammation. 
In support of these observations, eNAMPT circulating levels are increased in 
cancer patients compared to healthy subjects49-51. Furthermore, a positive 
correlation between circulating levels of eNAMPT and cancer progression 
has been described15-17 (Table 2).  
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Table 2. eNAMPT as a cancer biomarker 
  
Despite these encouraging results, there are, however, still numerous aspects 
to be revealed about the role and the biological importance of eNAMPT: (i) 
there is no information, in literature, about the physiological levels and role of 
eNAMPT, (ii) circulating eNAMPT levels, as described above, have been 
observed elevated in different pathologies and not only in cancer patients, and 
therefore there is no specificity associated to this phenomenon; (iii) different 
cells types, such as inflammatory cells, endothelial cells and adipocytes release 
eNAMPT and it is difficult to understand the source of circulating eNAMPT. 
In this regard, our group, recently, demonstrated that part of circulating 
eNAMPT derives directly from tumoural cells12.  
 
2.4 eNAMPT: neuro- and cardio- protection  
 
While in cancer and autoimmune disorders eNAMPT seems to have 
predominantly a negative role, increasing the aggressiveness of the tumour and 
inducing inflammatory responses, in brain and heart the picture appears 
different, with a cardio-protective and neuro-protective described.  
Evidences demonstrate that eNAMPT protects from apoptosis, induces 
proliferation and DNA synthesis via the activation of PI3K, p38, ERK 1/2 and 
NF-κB in cardiomyocytes52, 53. By doing this, eNAMPT reduces post-
reperfusion myocardial injury. In neurons, eNAMPT treatment increases 
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mRNA levels of COX-2, TNF and IL-1β via ERK 1/2, resulting in neurite 
outgrowth, protection from apoptosis induced by OGD (oxygen-glucose 
deprivation) and regulates glucose metabolism11. 
In conclusion, there is ample evidence that eNAMPT triggers numerous 
intracellular signalling pathways and it can also participate in many biological 
processes. The discrepancies observed may suffer from poor systematic 
investigation and may be translated in different roles of this cytokine dependent 
on the type of context in which it exerts its actions, both physiological and 
pathological.   
 
3 eNAMPT EFFECTS: ENZYMATIC ACTIVITY OR BINDING TO 
A RECEPTOR? 
 
The manner by which eNAMPT triggers the above phenomena is still largely 
unknown. Given that eNAMPT has the potential to remain enzymatically 
active upon release, these effects can be attributed to (i) its extracellular 
enzymatic activity and/or to (ii) the binding and activation of a cell surface 
receptor (Figure 1). Currently, there are evidences both for and against these 
possibilities, which are not mutually exclusive. 
 
3.1 Enzymatic activity of eNAMPT 
 
Revollo et al. demonstrated through size exclusion chromatography that 
secreted eNAMPT can exist as a dimer in conditioned media of adipocytes19. 
Given that dimerization is required for the creation of the catalytic site of the 
enzyme, this represents the possibility that eNAMPT might be active in the 
extracellular space. Obviously, the availability of substrates is crucial for this 
hypothesis, and the presence of sufficient concentrations of phosphoribosyl 
pyrophosphate (PRPP), nicotinamide or ATP has been disputed54. 
In this regard, a recent work of Li et al. has reported that eNAMPT protects 
macrophages from apoptosis induced by ER-stress through its enzymatic 
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activity55. It is true that if eNAMPT acts as an active enzyme, its product, 
NMN, should be able to mimic the effects of eNAMPT exposure. While a 
minority of experiments have confirmed this, many others have failed to 
demonstrate an effect of NMN19, 55. Indeed, some reports have shown no effect 
of NAMPT inhibitors on its function, demonstrating that at least part of its 
effects are independent of enzymatic activity26, 55.  
Indeed, the mutants of eNAMPT: H247E, R392A, R311A (that lead to a loss 
in enzymatic activity) and S200D (that prevents the dimerization of proteins), 
have the same ability compared to wild-type protein to protect macrophages 
from apoptosis induced by ER-stress, to induce the activation of STAT3 and 
to stimulate the release of IL-6. Only one report in the literature has shown that 
treatment with wild-type eNAMPT, but not with the H247A enzymatically 
inactive mutant, attenuates the detrimental effect of OGD on cell viability of 
neuronal and glial cells11.  
To date, it is still difficult to define if eNAMPT acts as an extracellular enzyme 
to induce intracellular pathway activations. 
 
3.2 Putative eNAMPT receptors 
 
Since the effects of eNAMPT are observable at ng/mL concentrations and the 
activation of specific intracellular pathways occurs in minutes, eNAMPT may 
bind to and activate a cell surface receptor. In 2007, the insulin receptor was 
the first propose by Fukuhara et al., but the article was subsequently retracted 
because the data were not reproducible8, 56. Only recently, other two different 
receptors were proposed: CCR5 and TLR4 but, up to date, no other research 
group has replicated or disputed those receptors. 
Van den Bergh et al. have reported that eNAMPT inhibits HIV infection of 
macrophages by R5 HIV and not by X4 HIV, moreover using the Surface 
Plasmon Resonance found an interaction between CCR5 and eNAMPT with a 
nanomolar range affinity57. Unfortunately, there are no information about the 
physiological role of this interaction. In 2015, Camp et al., also have reported 
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that eNAMPT binds and activates TLR4 inducing NF-κB activation in lung 
injury. The authors confirmed this interaction using Surface Plasmon 
Resonance, but without indicating either a KD or an affinity range58. 
Despite these evidences, the real identity of the receptor still remains unclear, 
and CCR5 or TLR4 may be reputed good candidates at best, given the 
incomplete data available. 
Most of my thesis has been focused on exploring the possibility that CCR5 is 
the eNAMPT receptor, and my observations will be submitted soon for 
publication. Given that the chapter on CCR5 is written in a manuscript-like 
format, with only minor information given about this receptor, I will expand 
this information below. On the contrary, given that only preliminary evidence 
have been provided by myself on TLR4 and this is too preliminary for 
publication, the corresponding chapter is not yet publication-ready and I have 
included TLR4 details there. 
 
4 CHEMOKINE RECEPTOR TYPE 5 (CCR5) 
 
CCR5 (also known as CD195) is the C-C chemokine receptor type 5, which 
binds selectively the chemokines of the CC-family. Chemokine receptors are 
members of the family of seven transmembrane-spanning receptors that signal 
through heterotrimeric G proteins upon ligand binding 59-61. In general, the 
effects of CCR5 include inhibition of cAMP production, stimulation of calcium 
release, activation of PI3-kinase and MAP kinases, as well as other tyrosine 
kinase cascades. Through these pathways, CCR5 regulates trafficking and 
effector function of immune cells and serves as the main co-receptor for the 
entry of R5 strains of the human immunodeficiency virus (HIV-1, HIV 2)60.  
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4.1 CCR5 signalling  
 
Endogenous agonists: 
A number of inflammatory CC-chemokines, including macrophage 
inflammatory protein 1 alpha (MIP-1α) and MIP-1β, chemokine (C-C motif) 
ligand 5 (CCL5 also known as RANTES), monocyte chemotactic protein 2 
(MCP-2 also known as CCL8) and HCC-1, structurally related to MIP- 1α, 
have been described as endogenous ligands of CCR5. 
 
Signal transduction of CCR5 induced by binding with the ligand, starts with 
the dissociation of G-protein into Gαi and Gβγ subunits and the consequent 
inhibition of adenylate cyclase and the activation of phospholipase Cβ isoforms 
(PLCB). These events lead to the hydrolysis of the phospholipid 
phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol-1,4,5- trisphosphate 
(IP3) and diacylglycerol (DAG). Then, the increase of IP3 production causes 
calcium release from the endoplasmic reticulum and the activation of several 
calcium- dependent signalling. Like other Gi-coupled receptors, also CCR5 
stimulates the opening of inward-rectifying K+ channels and activates different 
tyrosine kinase cascades62, 63. 
CCR5 ligands stimulate the activation of several intracellular pathways. Some 
of them involve the MAP kinase family, such as ERK1/2, p38 and JNK, 
p56Lck, the phosphatases SHP1 and SHP2, leading to the phosphorylation of 
Src-related kinase and the cytoskeleton associated protein kinases paxillin64, 65. 
Another one involves JAK-STAT signalling. The activation of JAK by 
RANTES leads to the translocation of STAT1-3 to the nucleus and the 
regulation of gene transcription66-68. 
All these RANTES-mediated signalling are inhibited by pertussis toxin (PTx), 
suggesting a Gαi mechanism69, 70, except for the JAK-STAT pathway67.  
Moreover, RANTES has also been shown to promote the activation of PI3 
kinase and Rho A, a member of the Rho family of small GTPases, in T cells71. 
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Rho GTPases, including Rho A, coordinate the reorganization of the actin 
cytoskeleton and regulate cell polarity, adhesion and motility. 
 
The modulation of CCR5 activity by its endogenous agonists includes also a 
physical conformational change, which results in the receptor internalization. 
Indeed, after ligand binding, the G-protein–coupled receptor kinases (GRK2 
and GRK3) phosphorylate the receptor and, subsequently, the β-arrestin 
recognises the phosphorylated receptor and mediates the internalization 
through clathrin-coated vesicles62, 63.    
 
 
Figure 3. CCR5 intracellular signalling pathways72. 
 
Endogenous antagonists: 
The chemokine Monocyte Chemotactic Protein-3 (MCP-3 also named CCL7) 
is a natural antagonist proposed for CCR5 receptor73. It competes with MIP-
1β on CCR5 and reduces MIP-1β- dependent calcium signalling73. Blanpain et 
al., demonstrated that MCP-3 is able to reduce the binding of the virus 
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membrane glycoprotein gp120 to CCR5 over-expressing CHO cells, but this is 
not translated into a reduction of the HIV infection73. 
Uguccioni et al., reported that MCP-3 induces a migration response with 
bimodal concentration dependence, with different efficacy and curve trends. In 
detail, MCP-3 increased monocyte migration until the concentration of 100 
nM, while higher concentrations inhibit the cell migration. They discovered 
that the effects of agonism obtained at low doses were mediated by CCR1, 
CCR2 and CCR374. 
 
Synthetic antagonists: 
The development of CCR5 inhibitors is mainly due to the need to find drugs 
that can reduce and prevent HIV R5 strain infection. Different small molecules 
have been synthetized such as maraviroc, cenicriviroc, aplaviroc and 
vicriviroc. 
Maraviroc is a synthetic competitive antagonist of CCR5. It reduces both 
RANTES- mediated calcium signalling and HIV infection, without affecting 
the internalization rate of the receptor75. Maraviroc is defined as a slowly 
reversible small molecule antiretroviral drug, classified as an entry inhibitor, 
which impedes gp120 binding to CCR5 and the consequent fusion of the virus 
with the host75, 76. It is used in the treatment of HIV R5 strains positive patients 
and, recently, entered into phase II for HIV pre-exposure prophylaxis (PrEP) 
in woman and men77, 78.  
Maraviroc is the only drug of this class approved for HIV therapy, while the 
other compounds failed in primary efficacy endpoints (vicriviroc) or showed 
liver toxicity (aplaviroc) in clinical trials79. Clinical trials with cenicriviroc are 
still ongoing. 
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4.2 CCR5 and inflammation 
 
CCR5 is largely expressed on resting T-lymphocytes with memory/effector 
phenotype, and on monocytes, macrophages and immature dendritic cells80, 81, 
and is up-regulated by pro-inflammatory cytokines82, 83. 
CCR5 plays an important role in the fate of CD8+ T cells. Indeed, upon entering 
the lymph nodes, naive CD8+ T cells are activated and quickly express CCR5 
on the cellular membrane. The subsequent contact between CD8+ T cells and 
antigen-mediated dendritic cells promotes the development of CD8+ T cells 
responses and the acquisition of immune memory. The effector T cells which 
express CCR5, subsequently exit from the lymph nodes and are recruited into 
sites of inflammation and/or infection by chemokines that are released by 
innate immune cells84-87.  
Moreover, CCR5 plays an important role in the fate of monocytes, 
macrophages and dendritic cells. Indeed, upon infection, tissutal macrophages 
produce a large amount of chemokines, among which some lead to CCR5 
activation. This contributes to the survival of macrophages during 
inflammation and infection, and drives and retains the macrophages and 
dendritic cells in inflammed tissue88.  
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Figure 4. CCR5 effects on immune cells 
 
 
Infections 
The role of CCR5 in infection is well documented. First, CCR5-/- mice develop 
normally in a pathogen free-environment, but exhibit a partial deficiency in 
macrophage function resulting in: (i) a reduction of Listeria infection 
clearance; (ii) a delay in hypersensitivity reactions and (iii) an increase of 
humoral responses to T-cell- dependent antigenic challenge89, 90.  
In particular, CCR5 plays an important role in human immunodeficiency virus 
(HIV) infection. In detail, CCR5 is the co-receptor used by M-tropic HIV, 
while CXCR4 is the co-receptor used by T-tropic HIV91, 92(Figure 5). In the 
first stage of HIV infection, the gp120 glycoprotein of HIV interacts with CD4 
and, after a conformal change, it binds to CCR5.  
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In the second stage, the interaction between gp120, CD4 and CCR5 (or 
CXCR4) leads to exposure of the gp41 subunit on the virus envelop which 
anchors the membrane of the host and mediates the HIV fusion process crucial 
for the infection93-96. 
 
Figure 5. Scheme of HIV infection (hivbook.com) 
 
 
Furthermore, CCR5 delta 32 (CCR5Δ32) is a mutant allele of CCR5 frequent 
in populations of European origin, and encodes a non-functional truncated 
protein that is not transported to the cell surface. Homozygotes for the Δ32 
allele exhibit a strong resistance to HIV R5 strain infection, whereas 
heterozygotes display delayed progression to acquired immunodeficiency 
syndrome (AIDS). Many other alleles affect the primary structure of CCR5 or 
its promoter, some of which lead to a non-functional receptor or otherwise 
influence AIDS progression97-101.  
 
Autoimmune diseases 
To evaluate the CCR5 mediated effects, most of the studies have taken 
advantage from the CCR5 KO mouse model and from pharmacogenetic 
analysis of patients (i.e. CCR5 Δ32 mutants).  
For example, the mutant Δ32 allele is associated: (i) to a milder phonotype in 
rheumatoid arthritis102 (ii) to a decrease risk of rejections in renal 
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transplantation103, (iii) to a decrease risk of atherosclerotic plaque formation 
and a protection against an early episode of myocardial infraction104, 105. 
 
Neuroinflammation 
Epidemiological studies reveal that CCR5Δ32 allele is associated with less 
severe forms of multiple sclerosis, but do not affect the risk of patients to 
develop the disease, suggesting that antagonism of CCR5 might reduce 
multiple sclerosis progression106 but also that CCR5 is not involved in its 
development. 
 
4.3 CCR5 and cancer 
 
Large amount of evidence describes CCR5 as crucial in cancer pathology, 
although most of these refer to pre-clinical studies conducted on cancer cells 
and tumour-bearing mouse models.  
CCR5/RANTES axis activation may have a double role in cancer: on one hand, 
it induces an immune response against cancer cells107, on the other hands, it 
appears to promote cancer progression and metastasis formation108. These 
contradictory effects may be explained, at least in part, with the ability of 
RANTES to also bind receptors (e.g. CCR1 and CCR3) other than CCR5. 
The activation of CCR5 leads to cancer cell proliferation, angiogenesis, 
modulation of extracellular matrix, and immune evasion mechanisms. Indeed, 
exogenous RANTES stimulates cell migration and invasion through the 
activation of PI3K/AKT and αvβ3integrins109, and by releasing MMP-2 and 9 
through NF-κB, ERK and Rac signalling pathways110-113.  
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Figure 6. CCR5 in cancer114 
 
Increase in glucose uptake and ATP production and enhanced glycolysis are 
consequences of CCR5 stimulation in cancer cells, favouring their 
proliferation115, 116.  
Moreover, different types of cancer, such as breast, melanoma, colorectal, 
ovarian and prostate cancer, over-express both CCR5 and RANTES117-123, a 
selection advantage that contributes to increase ability of cell migration and 
invasiveness. Specifically, in primary melanoma and some cutaneous 
metastasis RANTES and CCR5 have been found over-expressed compared to 
normal melanocytes and their expression correlates with malignancy state118, 
119. To understand the role of RANTES/CCR5 axis in melanoma, Song et al. 
generated a melanoma model in CCR5 knockout (CCR5−/−) and wild type 
(CCR5+/+) mice and observed that melanoma growth was delayed in CCR5-
deficient mice due to an increased cell death and activation of apoptotic 
signalling124.  
RANTES/CCR5 may also perturb the equilibrium of tumour infiltrating cells 
in the tumour microenvironment. In fact, RANTES promotes the recruitment 
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of tumour-promoting cells such as tumour associated macrophages (TAMs) 
and myeloid derived suppressor cells (MDSCs), that leads to immuno-
suppressing effects and reduce the antitumor T-cell activities117, 125, 126.  
Last, few information are available regarding cancer patients and CCR5 
signalling. Yet, in breast cancer, Niwa et al. and Bieche et al. found a 
correlation between RANTES and cancer progression, relapse and metastasis 
formation compared to patients in remission127, 128.  Moreover, Luboshits et al. 
showed that RANTES release was mostly due to cancer cells, but also 
infiltrating leucocytes and mesenchymal stem cells (MSCs), present in the 
tumour microenvironment, contribute to increase RANTES levels in 
patients129.  
 
5 TLR4: toll-like receptor 4 
  
Toll-like receptors (TLRs) are type I transmembrane proteins and belong to 
pattern recognition receptor (PRR) families. Their extracellular domain 
contains leucine-rich repeats (LRRs) and binds to a specific ligand unique to 
bacteria, fungi and viruses: lipopeptides are recognised by TLR2, 
lipopolysaccharide by TLR4 and flagellin by TLR5, while virus compounds 
such as RNA single- and double-strand are recognised by TLR8130-133. The 
activation of TLR receptors induces an inflammatory response through the 
cytosolic domain, which is conserved to all TLR receptors. The intracellular 
regions are similar to the cytosolic domain of IL-1 receptor and it is called 
Toll/IL-1 receptor (TIR) domain.  Moreover, TLRs are able to heterodimerise 
with other types of TLRs, TLR2 dimerises with TLR6 or with TLR1 to respond 
to diacylated or triacylated lipoproteins134. 
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Scheme 1. TLRs signalling135 
 
 
5.1 Signalling of TLR4 
 
Endogenous agonists: 
TLR4 is activated by a variety of pathogen-associated molecular patterns 
(PAMPs), among which the most characterized is lipopolysaccharide (LPS). 
LPS is not the only ligand of TLR4, but there are also glucoronoxylomannan, 
mouse mammary tumour virus envelope protein, fibrinogen, heat shock protein 
(HSP) 60 and 70, high-mobility group box 1 protein (HMGB1) and others. In 
addition to PAMPs, TLR4 can be also activated by damage-associated 
molecular patterns (DAMPs) derived from damaged tissues, such as 
oligosaccharides of hyaluronic acid, fibronectins, and fatty acids in response 
to cellular damage136-139.  
Yet, LPS remains the main agonist of TLR4 and it is composed from 3 different 
regions: the endotoxin (or lipid A), the core composed by oligosaccharides and 
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the O-antigen region140. The endotoxin is the only part of LPS recognised by 
TLR4, and the binding of endotoxin with TLR4 requires some different adaptor 
or accessory molecules, such as lipopolysaccharide-binding protein (LBP), 
CD14 and MD-2141-143.  
LPB: it is produced in the liver and in the lung and present into the blood. LPB 
does not participate in the TLR4 binding, but enhances the sensibility to 
LPS141. Indeed, LPB is a lipotransferase that facilitates the transfer of LPS onto 
CD14. Indeed, mice lacking LPB (LPB-/-) showed a reduction of LPS 
responses144, 145.  
CD14: it exists in 2 forms: a GPI-linked and a soluble form. CD14 lacks in a 
transmembrane and in a cytoplasmic region and it is not able to produce an 
intracellular signalling. Otherwise, soluble CD14 plays an important role in 
increasing the sensitivity to LPS in cells143. 
MD-2: it is essential to LPS responses. Indeed, the lack of MD-2 in cells leads 
to a lack of LPS response. In this context, different research groups have 
achieved conflicting results when they transfect TLR4 in HEK293T cells, 
indeed, some report showed a response of LPS in these cells146, while some 
others did not observed any responses. These conflicting results were due to a 
lack of MD-2 in HEK293T, while subsequent studies demonstrated that MD-
2 is also a soluble TLR4 co-receptor and its presence in serum might be 
sufficient to make cells responsive to LPS146-149. 
The activation of TLR4 induced by MD-2/LPS leads to a recruitment of four 
different TIR-domain-containing adapter molecules, which lead to activation 
of two different pathways: (i) the MyD88-dependet pathway and (ii) the 
MyD88-independet pathway.  
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Scheme 2. Mechanism of LPS activation of TLR4150 
 
(i) The MyD88-dependent pathway requires the recruitment of myeloid 
differentiation factor 88 (MyD88) and TIR-domain-containing adapter protein 
(TIRAP), which are involved in the early activation of NF-κB and the 
consequent production of different cytokines, such as IL-12 and IL-6151-154. 
MyD88 recruits IL-1R-associated kinase-1 (IRAK1) and the adaptor molecule 
TNF Receptor-Associated Factor 6 (TRAF6)155. The fundamental role of 
MyD88 was demonstrated by Shizuno et al. that showed that macrophages 
obtained from MyD88-deficient mice were insensitive to LPS-induced death 
and were not able to release some cytokines such as IL-6 and TNFα156. In brief, 
the activation of MyD88 triggers the activation of TRAF6 which in turn 
induces transforming growth factor-β-Activated Kinase 1 (TAK1). All these 
events culminate with the activation of MAPK and IκB kinase (IKK) that 
promotes NF-κB translocation into the nucleus.  
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(ii) The MyD88-indipendent pathway requires the recruitment of TIR-domain-
containing adaptor inducing interferon-β (TRIF) and TRIF-related Adaptor 
Molecule (TRAM). The activation of TRIF results in a strong activation of 
interferon (IFN)-regulator factor 3 (IRF3), involved in the late NF-κB 
activation, which culminates with the production of IFN-β and the expression 
of IFN-inducible genes134, 153, 157, 158.   
 
Antagonists: 
The antagonists of TLR4 interfere both with receptor dimerization or with the 
adapter recruitment, leading to a reduction in NF-κB and MAPK activation and 
to a decreased production of pro-inflammatory cytokines159, 160. 
To date, no endogenous antagonists of TLR4 are known, however recently 
several TLR4 inhibitors obtained from plant extracts have been identified. 
Particularly, many herbs used in Traditional Chinese medicine (TCM) and 
Ayurvedic medicine resulted rich in molecules acting as antagonists of 
TLR4161. These include green tea, Glycyrrhiza uralensis (licorice), Magnolia 
officinalis, ginger, Salvia miltiorrhiza, curcumin and Ganoderma lucidum159, 
160, 162-164. In detail, the main natural compounds that act as an antagonist of 
TLR4 are paclitaxel, morphine, opioids, sulforaphane, caffeic acid phenethyl 
ester and glycyrrhizin163, 165-168.  
Some synthetic compounds, such as naloxone, naltrexone, amitriptyline and 
imipramine, have been described as TLR4 antagonists169, 170.  
As alternative strategy, analogues of lipid A which act as antagonists of TLR4 
have been synthesized, such as LPS-RS and eritoran, which is currently 
undergoing clinical trials for use in treating Gram-negative endotoxemia and 
sepsis171, 172.  
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5.2 TLR4 and diseases 
 
Since the major ligand of TLR4 is bacterial LPS, it is clear that TLR4 covers 
an important role in inflammatory diseases, in particular in infections. 
However, TLR4 is related also with non-infection diseases such as cancer, 
cardiac disease, obesity and diabetes. 
 
Metabolic diseases   
TLR4 is expressed in many cell components of insulin target tissues, including 
liver, adipose tissue, skeletal muscle, vasculature, pancreatic β cells, and 
brain173, 174. 
Saturated Fatty Acids (SFAs) activation of TLR4 is an attractive link between 
obesity, insulin resistance and inflammation. SFAs are acyl components of 
LPS, which bind directly to TLR4/MD2/LPS and activate the receptor in 
vitro175, 176. However, recent studies document endotoxin contamination of 
experimental reagents, which generate false positive177-179.  
Extensive literature suggests that high fat diet-augmented postprandial 
endotoxemia is a possible mode by which dietary SFAs induce inflammation 
through TLR4 in diet-induced obesity models180. Moreover, insulin resistant 
diet-induced obesity and genetically obese mice exhibited elevated plasma LPS 
levels and endotoxemia, and it is correlated with insulin resistance. In addition, 
genetically obese mice treated with a LPS inhibitor showed a reduction in 
inflammation and metabolic abnormalities compared to untreated mice, 
suggesting a correlation of obesity with the TLR4 signalling181, 182. 
All these evidences suggest a correlation between obesity, inflammation and 
insulin resistance with the activation of TLR4. In this sense, different studies 
show that the alteration of TLR4 gene in mice confers protection from obesity-
induced inflammation and insulin resistance. In particular, using TLR4 
deficient mice (with loss-of function or deletion/mutations in the TLR4 gene), 
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different studies demonstrated that TLR4 signalling in macrophages and 
adipose tissue regulates whole body glucose homeostasis thought the effects 
on adipose, muscle, and liver tissues. Moreover, TLR4 deletion also improved 
insulin sensitivity, with higher rates of glucose disposal into skeletal muscle 
and adipose tissue183-187. 
 
Cardiac diseases 
An ischemia/reperfusion injury (I/R injury) is a hypoxic condition in which 
there is an interruption of the blood supply and a subsequent restoration. In 
addition to the damage caused by ischemia, the reperfusion of blood supply 
may cause an acute inflammatory response that leads to an extensive tissue 
injury named “reperfusion injury”188. Moreover, hypoxia induces the release 
of different damage-associated molecular patterns (DAMPs) from cells in 
response to a cell damage or tissue injury. DAMPs induce the activation of 
macrophages, which release pro-inflammatory cytokines, and the recruitment 
of neutrophils, monocytes, and lymphocytes in ischemic area189. Different 
studies, some of them conducted also in mice, demonstrated that DAMPs bind 
directly to TLR4 and activate its downstream pathways. Chong AJ et al. 
generated a TLR4 mutant mouse model, and observed a reduction of infarct 
size in I/R injury compered to wild type groups. Moreover, they reported a 
reduction in IL- 6 release and NF-κB and AP-1 activation190. Likewise, 
Shimamoto et al. demonstrated that the inhibition of TLR4 in a murine model 
of myocardial I/R injury results in a reduction of tissue damage172.  
 
Inflammation diseases  
The polymorphism studies conducted on the human TLR4 gene revealed 
diversifications among individuals, which determine different infection disease 
outcome.  
Two different TLR4 polymorphisms, the Asp299Gly and Thr399Ile variant 
alleles, were found to cause a reduction in LPS response191. Indeed, individuals 
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carrying these mutations showed a decreasing responsiveness to inhaled 
Escherichia coli LPS. Interestingly, Lorenz et al. observed in a comparative 
study between patients with septic shock, that patients with Asp299Gly and/or 
Thr399Ile polymorphisms were more susceptible compare to wild type. 
Moreover, these patients showed an increased sensitivity to gram-negative 
bacterial infections192. Unfortunately, other studies failed to confirm these data 
and the results were conflicting. Indeed, different research groups failed to 
observe any difference between patients with wild-type TLR4 and mutated 
TLR4. Ferwerda et al. reported that the primary cells obtained from 
Asp299Gly/Thr399Ile haplotypes patients did not show any different in LPS 
responsiveness compered to wild-type patient’s primary cells193, 194.  
Ferwerda et al., in a review, supposed that an erroneous study methodology 
can influence the results194. Indeed, they observed that four haplotypes exist 
for TLR4 genes: wild type/wild type, Asp299Gly /wild type, Thr399Ile /wild 
type, and Asp299Gly / Thr399Ile194. Moreover, recent data, obtained from the 
same research group, showed that only the Asp299Gly polymorphism differs 
from wild-type, indeed the blood samples obtain from Asp299Gly patients 
showed an increased TNF-α response after LPS-stimulation193.  
In addition, another single nucleotide polymorphism rs11536889 in 3′-
untranslated region of TLR4 was identified, and different studies reported a 
correlation between this polymorphism and periodontitis or organ failure in 
sepsis195. Subsequent studies showed that this polymorphism causes a 
reduction in cell surface expression of TLR4 and IL-8 production in response 
to LPS treatment196. 
 
Cancer 
A possible implication of TLR4 in tumour proliferation, metastasis formation 
and apoptosis inhibition has been supposed. 
First, an overexpression of TLR4 was found in many different types of cancer 
cells, such as lung cancer A549 and H460 cell lines197, cervical squamous 
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epithelial cells198, colon cancer cells and MDA-MB-231 human breast cancer 
cell line199.  
Moreover, a role of TLR4 in chemotherapy resistance and in pro-proliferative 
and pro-invasive stimulation of the tumour has been demonstrated. Indeed, 
Wang et al. reported in ovarian cancer a possible role of TLR4 in paclitaxel 
chemotherapy resistance200, while Hua et al. demonstrated that the silencing of 
TLR4 reduced cell invasion, survival, and tumorigenicity of prostate cancer201. 
Additionally, different studies observed that the TLR4 and MyD88 expression 
correlates with survival, metastasis formation and the expression of different 
chemokine such as CCL2 and CCL5202. Moreover, in H7402 (human liver 
cancer) and HepG2 (hepatoblastoma), LPS stimulation increased cell 
proliferation, chemotherapy resistance and NF-κB activation, which in turn 
leads to an increase of TNF, IL-6 and IL-8 release203-205. 
While on the one hand the expression of TRL4 in tumour cells is linked to a 
poor prognosis, on the other hand the expression of TLR4 on immune and 
inflammatory cells in tumour microenvironment leads to a production of pro-
inflammatory and immunosuppressive cytokine and angiogenetic mediators. 
This results in a polarization of tumour-associated macrophages (TAM), 
tumour-promoting cancer-associated fibroblasts (CAF), and the activation and 
accumulation of myeloid-derived suppressor cells (MDSCs)206-208.  
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During my Ph.D., I worked in two separate fields of research: (i) the 
investigation of novel chemicals as putative tubulin inhibitors; and (ii) the 
generation of data towards the identification of the eNAMPT receptor. Given 
that the articles describing novel tubulin agents have now been published1, my 
thesis work will concentrate on the more challenging, and so far unpublished, 
data attempting to unravel the eNAMPT receptor. 
In this latter aspect, I focused my attention on: 
(i) evaluating whether CCR5 could mediate the effects of eNAMPT, 
starting from the report that an interaction between eNAMPT and 
CCR5 determined by Surface Plasmon Resonance occurred2. 
 
(ii) Confirming the hypothesis emerged by Camp et al. that TLR4 may 
mediate part of the effects elicited by eNAMPT3. 
 
(iii) setting up different methodologies to discover new eNAMPT 
interactors, via fluorescent probes and cross-linking techniques.    
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ABSTRACT 
 
Extracellular nicotinamide phosphoribosyltransferase (eNAMPT, PBEF, 
Visfatin) is a metabokine released by various cell types with pro-tumoural and 
pro-inflammatory properties. In cancer, eNAMPT regulates tumor growth and 
metastasis formation through the activation of intracellular pathways, 
suggesting that eNAMPT acts through a putative receptor, although the nature 
of this receptor is still elusive. Recently, using Surface Plasma Resonance 
(SPR) it has been demonstrated that eNAMPT binds to the C-C chemokine 
receptor type 5 (CCR5), although the physiological meaning of this finding is 
still unknown.  
The aim of the present work was therefore to evaluate whether eNAMPT could 
act through the CCR5 receptor to explicate its effects in cancer cells. To study 
this phenomenon, B16 melanoma cells and a stable cell line that over-
expressed murine CCR5 (HeLa-CCR5) were used. eNAMPT, unlike 
RANTES, did not induce MAPK activation and calcium responses, two typical 
CCR5 signalling pathways, suggesting that eNAMPT does not act as an agonist 
of the receptor. Surprisingly, pre-treatment with eNAMPT resulted in the 
blockage of RANTES-dependent calcium signalling. In addition, eNAMPT did 
not modify other calcium signalling pathways triggered by ATP and carbachol, 
suggesting that the effect of eNAMPT may be specific for CCR5. This 
modulation in calcium signalling culminates with a delay in migration of 
melanoma cells in wound healing assays in vitro. Yet, eNAMPT does not act 
as an allosteric modulator of CCR5 since it does not modify CCR5 
internalization. 
Our work does not support the hypothesis that CCR5 is the elusive receptor for 
eNAMPT, but shows that exists a functional link between eNAMPT and CCR5 
signalling.  
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INTRODUCTION 
 
Extracellular nicotinamide phosphoribosyltransferase (eNAMPT), also known 
as PBEF or visfatin, is the secreted form of NAMPT, a key enzyme involved 
in maintaining the balance of NAD and ATP levels in cells1. This enzyme is 
now considered a metabokine secreted by different cells with pro-
inflammatory and pro-tumoural activity 2-4. Importantly, eNAMPT is over-
expressed in cancer 5, 6, where eNAMPT controls angiogenesis, tumour growth 
and metastasis formation 7-9. The stimulation of cancer cells with exogenous 
eNAMPT is sufficient to activate specific intracellular signalling pathways 
(e.g. STAT3, NF-κB, Akt, p3810-13) within minutes, which indicates that 
eNAMPT binds to and activates a cell surface receptor. Although the identity 
of this receptor remains unknown. The first receptor proposed was the insulin 
receptor, based on the insulin mimetic properties of eNAMPT14, however this 
article has been retracted15. Nonetheless, at least two others putative eNAMPT 
receptors have been proposed. Camp et al., demonstrated that eNAMPT 
induces lung inflammatory via direct ligation of Toll-like receptor 4 (TLR4)16. 
Moreover, computational analysis demonstrated that eNAMPT and MD-2, 
a TLR4-binding protein, share ~30% sequence identity16.  In 2012, was 
reported that eNAMPT selectively inhibits infection of macrophages by human 
immunodeficiency virus (HIV), this activity was linked, using SPR, to a direct 
interaction with the C-C chemokine receptor type 5 (CCR5; CD195)17.  
CCR5 is a seven transmembrane, G-protein coupled receptor (GPCR), belongs 
to the β-chemokine receptor, expressed by macrophages, T-cells, microglia, 
dendritic cells and cancer cells18. CCR5 is involved in inflammatory response, 
thought the regulation of trafficking and effector functions of immune cells and 
it also serves as a co-preceptor for the entry of HIV R5 strains19, 20.  Moreover, 
CCR5 is over-expressed in several cancers (e.g. breast cancer, melanoma) and 
it was suggested that the activation of CCR5 controls tumour development 
by acting as growth factors, stimulating angiogenesis, inducing the 
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recruitment of additional stromal and inflammatory cells, and taking part in 
immune evasion mechanisms21, 22. For example, in melanoma CCR5 
expression on stromal cells is necessary for the spread of B16 cells to the 
lungs23 and in CCR5-deficient mice the B16 growth is delayed 24. The 
activation of CCR5 receptor induces G-protein alpha-i family that results in a 
blockage of adenylate cyclase type I and then in a reduction of intracellular 
cAMP, PLC-γ activation and a calcium influx21, 25.  To date, the CCR5 ligands 
include the agonists RANTES (CCL5), MIP-1α and 1-β and CCL2-8-11-14, 
and the natural antagonist MCP-326.  
Starting from this proof of principle, the aim of our study was to shed light on 
whether eNAMPT may be a novel ligand for CCR5 in cancer cells. 
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MATERIALS AND METHOD 
 
Cell culture 
HeLa (human cervix carcinoma) and B16 (murine melanoma) cells were 
cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% 
foetal bovine serum (FBS), 2 mg/ml glutamine, 10 U/ml penicillin and 100 
µg/ml streptomycin (Sigma, St. Louis, MO, USA). Cells were maintained in a 
humidified incubator supplied with 5% CO2/95% air at 37°C.  
 
Recombinant eNAMPT preparation  
Wild-type murine full-length and H247E NAMPT (ORF GenBank BC018358) 
was cloned in pET28a (NdeI/EcoRI). Recombinant eNAMPTs were expressed 
in E. Coli (ClearColi, BL21(DE3)), inducted with IPTG 0.5 mM for 3 h at 
20°C, and purified by His-tag affinity chromatography with NiNTA Superflow 
resin (Qiagen).  
 
Generation of stable HeLa-CCR5 cell line  
Murine CCR5 was cloned in the pLV lentiviral vector. Correct insertion and 
sequence were confirmed by DNA sequencing. The lentiviral particles were 
produced as described elsewhere7 in HEK293T cells transfected with 
pMDLg/pRRE, pMD2.VSVG, pRSV-Rev and pLV-CCR5/pLV-empty 
plasmids. Briefly, after 48 h, cell medium was collected, filtrated and 
centrifuged for 1 h 30 min at 100 000 g. The viral particles, corresponding to 
the pellet fraction, were resuspended and used to infect HeLa cells, after virus 
titration. Stable scramble (HeLa-SCR) and HeLa-CCR5 were generated and 
CCR5 expression was monitored with Real Time PCR and FACS analysis.  
 
CCR5 internalization assay 
 5 × 105 cells were plated in 96-well plates and treated with vehicle, RANTES 
(Peprotech) and/or eNAMPT for 15, 30 or 60 minutes at 37°C or 4°C. Cells 
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were washed twice in PBS and resuspended in 100 µL of Phosphate Buffer 
saline (PBS) and stained with anti-CCR5 PE for 20 min at 4°C. Cells were then 
washed twice in PBS and resuspended in PBS. Cell surface expression of 
CCR5 analysis was determined with a BD Accuri FACS. 
 
Immunofluorescence 
Cells were fixed in 4% formaldehyde. Subsequently, primary and secondary 
antibodies were applied in 0.2% gelatin. Fluorescence images were acquired 
using a Leica Confocal microscopy.  
 
Fura-2 imaging 
Cells were loaded with 2 µM Fura-2-AM in KRB solution (Krebs-Ringer 
modified buffer: 125 mM NaCl, 5 mM KCl, 1 mM Na3PO4, 1 mM MgSO4, 5.5 
mM glucose, 20 mM HEPES, pH 7.4) supplemented with 2 mM CaCl2, 0.01% 
pluronic acid and 5µM sulfinpyrazone. After washing and de-esterification (30 
minutes), the coverslip was mounted in a chamber and placed on the stage of a 
Leica epifluorescent microscope equipped with a S Fluor 40×/1.3 objective. 
Cells were stimulated with the indicated treatments and excited at 340/380 nm 
by the monochromator Polichrome V (Till Photonics, Munich, Germany) and 
the fluorescent signal was collected by a CCD camera (Hamamatsu, Japan) 
through bandpass 510 nm filter; the experiments were controlled and images 
analysed with MetaFluor (Molecular Devices, Sunnyvale, CA, USA) software. 
To quantify the difference in the amplitude of Ca2+ transients, the ratio values 
were normalized according to the formula (ΔF)/F0 (referred to as normalized 
(norm.) ratio). The cells with norm. ratio above 0.2 were considered as 
responders and used for further analysis. 
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Western blot analysis 
5 × 105 cells were treated at the indicated time-points and the cells were lysed 
in 80 µL in lysis buffer composed of 20 mM HEPES, 100 mM NaCl, 5 mM 
EDTA, 1% Nonidet P-40+ Protease & Phosphatase Inhibitor Cocktail (Sigma). 
Proteins quantification was performed with BCA Protein Assay (Thermo 
Fisher Scientific, Waltham, MA, USA), and proteins were resolved on SDS–
PAGE. Densitometry analysis was performed with Quantity One program 
(Bio-Rad, Hemel Hempstead, UK). 
 
Wound-healing assay 
In vitro wound assays were performed using IBIDI Culture-Inserts according 
to Shih et al.27. Briefly, when confluent monolayers of B16 cells were 
established on IBIDI dishes (35 mm with high culture-insert coating), cells 
were washed twice with PBS to remove residual cell debris. Cells were then 
incubated with RANTES, eNAMPT and maraviroc or the combination of three 
for 24 h and pictures of a defined wound spot were made at different time 
points. The area of the wound in the microscopic pictures was measured using 
Image J software (National Institutes of Health, MD) at different time points. 
The percentage wound healing after 4, 6, 8 and 10 hours was calculated in 
relative to the total wound area at t = 0 h of the same wound spot. 
 
Binding experiment 
1 × 105 cells suspension were incubated with 2U/1 × 105 cells of Heparinise I 
and III for 1 hour at 4°C. Then, cells were washed and incubated with 
eNAMPT (27 µg) or maraviroc (10 µM) for 20 minutes at 4°C in complete 
medium. After, biotin-RANTES (25ng) conjugated with PE were added to 
cells suspension for 2 hours at 4°C. Then, cells were washed 3 times in ice cold 
PBS, resuspended in FACS Buffer (Hanks' Balanced Salt solution HBSS + 
0.5% BSA) and samples were analysed using a FACS (BD accuri).   
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Reagents 
Rabbit polyclonal antibody anti-p42/44 MAPK was from Cell Signalling 
Technology,; mouse anti-tubulin was from Sigma; peroxidase-conjugated 
secondary antibodies were from Biorad; maraviroc, ATP and carbachol were 
from Sigma, PE-anti mouse CCR5 from Biolegend. Recombinant 
RANTES/CCL5 was from Peprotech; biotinylated-reconbinant-RANTES was 
from ChemoTactis. DRAQ5 was from Thermo Fischer Scientific  
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RESULTS  
 
It has been demonstrated that eNAMPT binds to CCR5 through Surface 
Plasmon Resonance technique and that it is capable of inhibiting infections by 
R5 HIV in monocytes, although the relevance of this interaction in cancer has 
not been evalueted17. 4r 
To understand whether CCR5 could be the receptor for eNAMPT, at first, we 
decided to employ HeLa cells with stable over-expressing of CCR5 (HeLa-
CCR5) comparing them with scrambled HeLa (HeLa-SCR). We first evaluated 
whether this cytokine parallels the effects of RANTES, a known potent agonist, 
in CCR5-overexpressing HeLa cells. As it can be seen in Figure 1A-B, 
RANTES 25ng/ml was able to elicit a marked induction of p42/p44 ERK 
phosphorylation in a time-dependent manner. Yet, we were unable to see an 
effect with eNAMPT, in a range of concentrations between 250-1000 ng/ml, 
in the activation of this pathway (Figure 1A-B; concentrations of 250 ng/ml 
and 1000 ng/ml not shown). It is therefore likely that the receptor usually 
associated with eNAMPT is not CCR5.  
Calcium signalling has also been associated with CCR5 and we also evaluated 
this pathway. As it can be seen in Figure 1C-D, RANTES was able to induce 
calcium increases while eNAMPT was unable to do it. In support of this data, 
we investigated the ability of eNAMPT to induce CCR5 internalization, a 
common feature of CCR5 agonists. As expected RANTES induced a time and 
concentration dependent internalization of the receptor, however eNAMPT 
alone failed to modify the pattern of CCR5 (Figure 2A, B).  
In light of these results, it would not appear that CCR5 is the receptor 
responsible for the effects commonly associated to eNAMPT and that 
eNAMPT is not an agonist of CCR5. On the contrary, the pre-treatment of 
eNAMPT partially obstructed the RANTES-mediated CCR5 internalization, 
suggesting a possible antagonistic role. 
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We next tested whether eNAMPT was able to modulate the responses to 
RANTES. Co-incubation or pre-treatment of cells with eNAMPT did not 
modify the phosphorylation pattern of p42/p44 ERK. The effect of RANTES, 
as expected, was antagonized, by maraviroc, a known antagonist of CCR5 
(Figure 3A-B). Surprisingly, pre-incubation, but not co-incubation, with 
eNAMPT at both 250 and 500 ng/ml reduced significantly the calcium 
mobilization induced by RANTES. The effect of eNAMPT at the higher dose 
was quantitatively similar to maraviroc (Figure 4A-B). To evaluate whether 
the effect of eNAMPT on calcium signalling was specific, we evaluated the 
effect of the same concentration of eNAMPT on Ca2+-signalling induced by 
ATP or carbachol, whose receptors are present both in wild-type and HeLa-
CCR5 cells. As shown in Figure 4C-F, the antagonistic effect of eNAMPT was 
specific for CCR5 signalling, as the responses to ATP or CCh were unaffected. 
All these data suggest that eNAMPT blocks selectively the RANTES-
dependent calcium signalling. To test if this inhibition is mediated by the 
enzymatic activity or via binding to the receptor, we investigated the effect of 
a mutated and inactive form of eNAMPT called H247E eNAMPT. The pre-
incubation with H247E eNAMPT (500 mg/ml) reduced the calcium 
mobilization induced by RANTES (91.5 ± 3.28 % of responsive cells) in the 
same manner of the WT form (47.16 ± 11.47 % of responsive cells for H247E 
vs 45.58 ± 8.47 % of responsive cells for WT) (Figure 5 A-B). This data 
suggests that the reduction in calcium signalling by eNAMPT is mediated by 
a putative interaction with the receptor and not via its enzymatic activity.  
Moreover, the effect of eNAMPT could not be mimicked by the buffer in 
which the protein was dissolved, or by proteins isolated in the same manner 
such as nicotinamide mononucleotide adenylyltransferase (NMNAT) at 
identical concentrations (Figure 5). 
The effect observed was obtained in an artificious system, and we therefore 
decided to investigate the interaction between CCR5 signalling and eNAMPT 
in a system that has been reported to respond to both. In this respect, we chose 
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a melanoma cell line, B16, in which we have previously shown an effect of 
eNAMPT7. As expected, in this system, RANTES was able to induce a Ca2+-
response, which was blunted by the eNAMPT pre-incubation (Figure 6A).  
RANTES has been shown to promote migration in these cells, possibly via the 
calcium signalling pathway, and we confirmed this via the wound-healing 
assay. Briefly, RANTES, at a concentration of 200 ng/ml promoted wound 
closure compared to control in a time dependent manner (Figure 6B-C). This 
effect, as expected was antagonized by maraviroc and by eNAMPT, that per 
se had no effect on migration of these cells.  
Considering these results, it would appear that eNAMPT acts as a natural 
antagonist of CCR5. However, from our results we were not yet able to 
determinate whether eNAMPT binds directly to CCR5 or interferes with 
RANTES-mediated calcium signalling through another receptor.  
Therefore, we tested whether eNAMPT could directly bind to CCR5, taken 
advantage from a competitive binding assay. As it shown in Figure 7, pre-
incubation of eNAMPT reduced cell surface binding of biotinylated-RANTES 
conjugated with avidin PE in HeLa-CCR5 cells. The effect of eNAMPT was 
similar to maraviroc. Specifically, eNAMPT reduces the percentage of 
RANTES-PE positive cells of 24%, while maraviroc reduction was of 29% 
(Figure 7A).  The analysis of the mean florescence intensity (MFI) confirmed 
these results (Figure 7B).  
A binding assay performed with a labelled iodine CCL3, preferred to 
radioactive CCL5 because of nonspecific aggregation, in collaboration with 
professor Massimo Locati (Humanitas research centre) is still on going to 
confirm the data described above obtained using RANTES-PE.  
Since the crystal structure of RANTES in complex with CCR5 has been 
resolved, we performed an in silico analysis. Uniport alignment revealed 
similar amino acid sequence between eNAMPT and RANTES considering the 
chemical and physical properties of amino acids (Figure 8A). Surprisingly, 
these data were partially confirmed analysing the structure of eNAMPT and 
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RANTES using PyMol software. We identified a N-terminal alpha-helix of 
RANTES (black, Figure 8B), crucial for the binding with CCR5 (green, Figure 
8B), which was aligned with a loop of eNAMPT (orange, Figure 8B). 
Moreover, RANTES has three β-strands and one α-helix that co-participate to 
the binding with CCR5. These motifs are also present in eNAMPT (yellow, 
Figure 8B). Despite of eNAMPT is a 55 kDa protein with a greater steric 
hindrance compared to RANTES (9 kDa), the alignment with PyMol 
demonstrated that eNAMPT could interact with CCR5. Mutations in these 
emerged regions might be useful to evaluate the structure–function relationship 
between eNAMPT and CCR5. 
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Figure 1. (A) Western blot and densitometry analysis of phosphorylated p42/44 ERK after 2 
hours of starvation followed by treatment for 5 minutes with recombinant RANTES (25ng/mL) 
in serum-free condition in HeLa-SCR and HeLa-CCR5 cell lines. Representative data of 4 
separate experiments. (B) Western blot and densitometry analysis of phosphorylated p42/44 
ERK after 2 hours of starvation followed by treatment for 5 minutes with recombinant 
eNAMPT (500ng/mL) in serum-free condition in HeLa-SCR and HeLa-CCR5. Representative 
data of 3 separate experiments.  (C) Calcium traces in HeLa-SCR and HeLa-CCR5 loaded with 
FURA-2AM and stimulated with RANTES (25ng/mL). Representative traces of peak calcium 
concentrations reached are shown for 98–110 cells from 5 independent experiments.   (D) 
Calcium traces of HeLa-SCR and HeLa-CCR5 loaded with FURA-2AM and stimulated with 
eNAMPT (500ng/mL). Representative traces of peak calcium reached (90–102 cells from 7 
independent experiments). 
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Figure 2. (A) Flow cytometry analysis of HeLa-CCR5 cells treated with RANTES (50, 100, 
500 ng/mL) for 60 minutes in presence or absence of eNAMPT at 37°C, stained with anti-
mouse CCR5-PE and analysed using FACS BD accuri. The data are summarized in histograms 
and expressed as mean ± S.E.M. of 12 determinations from 4 separate experiments. (B) 
Confocal images of HeLa-CCR5 cells treated with RANTES (100 ng/ml) for 60 minutes in 
presence or absence of eNAMPT (500ng/ml) at 37°C, stained with anti-mouse CCR5-PE (Red) 
and DRAQ5 (nuclear marker, blue). Representative images of 6 determinations of 3 separate 
experiments.  
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Figure 3. (A) Western blot and densitometry analysis of phosphorylated p42/44 ERK after 2 
hours of starvation followed by co-treatment for 5 minutes with recombinant RANTES (25 
ng/mL) in presence of eNAMPT (500ng/mL) or maraviroc (10 µM) or eNAMPT vehicle in 
serum-free condition in HeLa-SCR and HeLa-CCR5 cell lines. Representative data of 4 
separate experiments. (B) Western blot and densitometry analysis of phosphorylated p42/44 
ERK after 45 minutes of eNAMPT (500ng/mL) or maraviroc (10 µM) or eNAMPT vehicle 
pre-incubation followed by treatment for 5 minutes with recombinant RANTES (25 ng/mL). 
Representative data of 4 separate experiments.  
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Figure 4. (A) Representative calcium traces of HeLa-CCR5 loaded with FURA-2AM and 
treated with RANTES (25 ng/ml) alone or pre-treated with eNAMPT (250ng/mL or 500 ng/ml) 
or maraviroc (3 µM) for 100 sec. High dose of ATP (333 µM) was used to verify the ability of 
the cells to evoke normal calcium traces. (B) Histograms of responding cells (left panel) and 
% of max peak (right panel) as mean ± S.E.M. of % responding cell for slice. (248–410 cells 
from 6 to 11 independent experiments) **P < 0.01, ***P<0.001 versus ctrl. (C) Representative 
calcium traces of HeLa-SCR and HeLa-CCR5 loaded with FURA-2AM and treated with ATP 
(3 µM) alone or pre-treated with eNAMPT (500 ng/ml) for 5 minutes. (D) The data are 
summarized in histograms and expressed as mean ± S.E.M. of % max peak calcium response 
(120–190 cells from 5 to 9 independent experiments). (E) Representative calcium traces of 
HeLa-SCR and HeLa-CCR5 loaded with FURA-2AM and treated with CCh (300 µM) alone 
or pre-treated with eNAMPT (500 ng/ml) for 5 minutes. (F) The data are summarized in 
histograms and expressed as mean ± S.E.M of % max peak calcium response (105–185 cells 
from 5 to 9 independent experiments). 
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Figure 5. HeLa-CCR5 cells were loaded with FURA-2AM and treated with RANTES (25 
ng/ml) alone or pre-treated with eNAMPT (500 ng/ml) or eNAMPT-H247E (500 ng/ml) or 
NMNAT 2 (500 ng/ml) for 100 sec. Histograms of responding cells (left panel) and % of max 
peak (right panel) as mean ± S.E.M. of % responding cell for slice. (180–210 cells from 3 
independent experiments) *P<0.05, **P < 0.01, versus ctrl.  
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Figure 6. (A) Representative calcium traces of B16 cells loaded with FURA-2AM and treated 
with RANTES (600 ng/ml) alone or pre-treated with eNAMPT (500 ng/ml) for 100 sec. (B) 
Time course of wound opening in B16 cells treated or not with RANTES (200 ng/ml), 
eNAMPT (500 ng/ml) or maraviroc (10 µM). Mean ± S.E.M. of 12 determinations from 4 
separate experiments. (C) Representative images of wound healing assay at 4 hours of 
treatment with RANTES (600 ng/ml) and/or eNAMPT (500 ng/ml) *P<0.05, ** P<0.01 
***P<0.001: * RANTES vs CTRL; + RANTES vs eNAMPT + RANTES.  
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Figure 7. Percentage of positive cell (A) and the mean florescence intensity (B) of RANTES-
PE binding on HeLa-CCR5 cells incubated or not with eNAMPT (27 µg, 100-fold increase 
compared to RANTES molar concentration) or maraviroc (10 µM). Mean ± SEM of 5 separate 
experiments. 
 
Figure 8. (A) Uniprot alignment of amino acid sequence between murine NAMPT and 
RANTES. (B) Analysis of NAMPT and RANTES using PyMol software. Full-length 
RANTES in black; CCR5 in green; NAMPT residues from 1 to 60 in yellow; NAMPT residues 
from 60-491 in orange. 
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Key finding: 
• eNAMPT is not an agonist of CCR5, since it is unable to induce ERK 
phosphorylation, calcium signalling and internalization of CCR5.  
• eNAMPT is an antagonist of CCR5, as it reduces RANTES-mediated 
calcium signalling and migration. 
• eNAMPT does not affect the internalization rate of CCR5 induced by 
RANTES. 
• eNAMPT binds to CCR5 and competes with RANTES.  
• Bioinformatics suggests structural similarities between RANTES and 
eNAMPT. 
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UNPUBLISHED RESULTS 
 
 
Is the Toll-Like Receptor 4 (TLR4) the eNAMPT receptor? 
 
 
Keywords:   eNAMPT, membrane receptor, TLR4, NF-κB pathway 
 
 
 
ASTRACT 
 
Camp et al. sustains that eNAMPT induces the activation of NF-κB through 
the direct binding to the Toll-like Receptor 4 (TLR4), demonstrated via the 
Surface Plasma Resonance (SPR) technique. In addition, using in silico model, 
they suggest that eNAMPT does not require MD-2 binding complex to activate 
TLR4. In this paragraph we tried to recapitulate Camp’s observations, even 
more experiments are necessary to draw a conclusion. 
To study the ability of eNAMPT to bind to and activate TLR4 in presence or 
absence of MD2, Jurkat CD4+ T cells and a stable cell line that over-expressed 
human TLR4 (HeLa-TLR4) were used. eNAMPT and LPS did not induce NF-
κB activation in MD2 lacking cells (HeLa-TLR4). Surprisingly, eNAMPT was 
able to induce NF-κB activation in CD4+ T cell line Jurkat, (which expressed 
MD-2) after 1 hour of treatment. These data suggest that eNAMPT probably 
required MD2 to explicate its effects on TLR4. Moreover, gene expression 
analysis reveals similarities in genes up-regulation evoked by eNAMPT and 
LPS, but results are not superimposable.   
Our work does not support the hypothesis that TLR4 is the elusive receptor for 
eNAMPT, but shows that exists a functional link between eNAMPT and TLR4 
signalling. 
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INTRODUCTION  
 
One mechanism by which the immune system senses pathogens is through the 
Toll-like receptors (TLRs), which recognize microbial components1-4. TLRs 
are type I transmembrane proteins expressed on the membranes of immune 
cells, including macrophages, B and T cells and dendritic cells, but also 
fibroblast and endothelial cells. In humans, to date 11 functional TLRs have 
been identified, and their stimulation induces different patterns of gene 
expression which lead first to the activation of the innate immune system and 
second to the development of antigen-specific acquired immunity5.  
TLR4 plays an important role in controlling innate immune responses after 
infection, but has been found involved also in other disorders including cancer, 
cardiac disease, obesity and diabetes. 
TLR4 is activated by a variety of pathogen-associated molecular patterns 
(PAMPs), among which the most characterized is lipopolysaccharide (LPS). 
In addition to PAMPs, TLR4 can be also activated by damage-associated 
molecular patterns (DAMPs) derived from damaged tissues, such as 
oligosaccharides of hyaluronic acid, fibronectins, and fatty acids in response 
to cellular damage7-10.  
Recently, Camp et al., reported through the Surface Plasmon Resonance (SPR) 
technique that the extracellular nicotinamide phosphoribosyltransferase 
(eNAMPT) binds to TLR4 and it is able to activate NF-κB downstream32. They 
demonstrated that eNAMPT induced the activation of NF-κB and the 
expression of NF-κB signalling genes in pulmonary endothelial cells and that 
this effect was reverted by the pre-treatment with TLR4 inhibitors (e.g. RS-
LPS, CLI-095 and OxPAPC). Moreover, through the use of monoclonal 
antibodies against eNAMPT and TLR4, they have demonstrated the 
dependence of TLR4 in eNAMPT-mediated NF-κB activation. In support of 
this, eNAMPT-induced lung inflammation was reduced in TLR4−/− mice 
compared to wild type mice32.   
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eNAMPT is a cytokine released by various cell types with autocrine and 
paracrine effects27, 28. The first evidence of a relevant role of eNAMPT in 
immunity was the identification of its capacity to synergize with IL-7 and SCF 
to stimulate B-cell differentiation29. From this first observation, several studies 
have been conducted and now we know that several inflammatory stimuli 
induce the secretion of eNAMPT, especially from innate immune cells, such 
as monocytes, neutrophils, and macrophages. Furthermore, eNAMPT per se 
has pro-inflammatory properties. For example, eNAMPT controls the 
differentiation of resting monocytes, proliferation and polarization of 
macrophages27. In these cells, the treatment with recombinant eNAMPT 
induces the activation of different pathways such as STAT3, NF-κB, Akt and 
ERK1/2, suggesting the presence of a receptor that mediates these effects30, 31.  
Starting from these evidences, we decided to further investigate the possibility 
that TLR4 was the eNAMPT receptor.  
 
MATERIALS AND METHODS 
 
Cell culture 
HeLa (human cervix carcinoma) and Jurkat (CD4+ T cell line) cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
10% foetal bovine serum (FBS), 2 mg/ml glutamine, 10 U/ml penicillin and 
100 µg/ml streptomycin (Sigma). Cells were maintained in a humidified 
incubator supplied with 5% CO2/95% air at 37°C.  
 
Recombinant eNAMPT preparation  
Wild-type murine full-length NAMPT (ORF GenBank BC018358) was cloned 
in pET28a (NdeI/EcoRI), expressed in E. Coli (ClearColi, BL21-DE3), 
induced with IPTG 0.5 mM for 3 h at 20°C) and purified by His-tag affinity 
chromatography with NiNTA Superflow resin (Qiagen). 
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Limulus amebocyte lysate (LAL) test 
Endotoxin levels were determined with the ToxinSensor Chromogenic LAL 
Endotoxin Assay kit according to manufacturer's instructions. Briefly, 
reconstitute LAL was added to eNAMPT samples and incubate 40 minutes at 
37°C. Then, chromogenic substrate solution was added to each sample and 
incubate for 6 minutes at 37°C. Subsequent, the Colour-stabilizer was added to 
stop the reaction and absorbance of samples were acquired at 545 nm using the 
spectrophotometer Victor3 (Perkin Elmer).   
 
Generation of stable HeLa-TLR4 cell line 
Human TLR4-YFP plasmid was purchased from AddGene. HeLa cells were 
transfected using lipofectamine 2000 with Human TLR4-YFP or PCDNA-
empty vector and after 48 h cells were maintained in medium supplemented 
with neomycin at 500 ng/mL for cells selection for the generation of stable 
HeLa-TLR4 and HeLa-SCR (scramble) cell lines. The relative expression of 
TLR4-YFP was determined by flow cytometry (BD accuri).  
 
Western blot analysis 
5 × 105 cells were treated at the indicated time-points with or without eNAMPT 
or LPS (581-009-L002 Alexis Biochemicals) and then lysed in 80 µL in lysis 
buffer (20 mM HEPES, 100 mM NaCl, 5 mM EDTA, 1% Nonidet P-40+ 
Protease & Phosphatase Inhibitor Cocktail (Sigma)). Proteins quantification 
was performed with BCA Protein Assay (Thermo Fisher Scientific, Waltham, 
MA, USA), and proteins were resolved on SDS–PAGE. Densitometry analysis 
was performed with Quantity One program (Bio-Rad, Hemel Hempstead, UK). 
Mouse anti-tubulin was from Sigma; peroxidase-conjugated secondary 
antibodies were from Biorad. P-NF-κB (p65) at Ser536 was from Cell Signalling 
Technology. 
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Peritoneal exudate cells (PECs) isolation  
Peritoneal exudate cells (PECs) were elicited by injecting i.p. 1 ml of 
thioglycolate (3% in H2O) into 8-weeks old C57BL/6 mice. After 4 days, cells 
were recovered from the peritoneal cavity by lavage using 5 ml of PBS. Cells 
were plated in 6-well plates for 1 h at 37°C. Non adherent cells were removed 
by washing the wells three times with ice-cold PBS. Macrophages were treated 
with eNAMPT or LPS for indicated time points.  
 
RT-PCR 
Total mRNA was extracted using QIAzol Lysis Reagent (Quiagen, Milan, 
Italy) and retro-transcribed to cDNA using ImProm-II RT system (Promega, 
Milan, Italy). Real-time PCR was performed using SYBR Green according to 
manufacturer's instructions (Biorad) on a SFX96 Real-time system (Biorad, 
Segrate, Italy). For normalization of the raw qPCR data, S18 ribosomal subunit 
housekeeping gene was used. 
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Results 
Camp et al., demonstrated that eNAMPT induces the activation of NF-κB 
through the binding to TLR4. In addition, they suggested that eNAMPT, 
conversely to LPS, does not require MD-2 binding complex to activate TLR4.  
Indeed, using an in silico model, they demonstrated that a similarity exists 
between the loop region of eNAMPT and MD-2 involved in TLR4 binding32. 
First of all, we decided to produce a recombinant eNAMPT protein in 
endotoxin-free bacteria to avoid unspecific activation of TLR4 due to a 
probable LPS contamination. After the purification of eNAMPT, the endotoxin 
content was determined by LAL test and as expected the level of endotoxins 
was <0.1 EU. 
We generated a stable HeLa cell line overexpressing TLR4 (HeLa-TLR4) and 
scramble HeLa (HeLa-SCR) cell line as control. It is known that HeLa cells 
lack of MD-2 expression and we decided to use this model to investigate the 
ability of eNAMPT to induce NF-κB activation, monitored through the p65 
phosphorylation33, 34.  
As expected, in MD-2-deficient cells (HeLa-SCR; HeLa-TLR4) the treatment 
with LPS (100 ng/ml) was not able to induce p65 phosphorylation (Figure 1A-
B). Unfortunately, we failed to observe a significant phosphorylation of p65 
upon eNAMPT-treatment at different time points (Figure 1A-B).  
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Figure 1. Western blot (left) and densitometry (right) analysis of phosphorylated p65 after 2 
hours of starvation followed by treatment for indicated time points with recombinant eNAMPT 
or LPS in serum-free condition in HeLa-SCR (A) and HeLa-TLR4 (B) cells. Representative 
data of 4 separate experiments. (t test * P<0.05; **P<0.01; ***P<0,001) 
 
 
 
We next evaluated whether the inability of eNAMPT to induce NF-κB in 
TLR4-overexpressing cells was due to the absence of MD-2. To do this, we 
next tested the ability of eNAMPT to induce NF-κB in CD4+ T cell line Jurkat, 
which expressed MD-2. 
The stimulation of LPS (100ng/mL) of Jurkat cells was able to elicit a marked 
increase of p65 phosphorylation in a time-dependent manner (Figure 2A). On 
the other hand, as shown in Figure 2B, eNAMPT treatment induced the p65 
phosphorylation at 15, 45 and 60 minutes, however the p65 phosphorylation 
was statistically significant only after 60 minutes of stimulation (Figure 2C).  
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Figure 2. Representative Western blot of phosphorylated p65 after 2 hours of starvation 
followed by treatment for indicated time points with recombinant LPS (A) or with recombinant 
eNAMPT (B) in serum-free condition in Jurkat cell line. (C) Densitometry analysis of 
phosphorylated p65 after LPS or eNAMPT treatment. Representative data of 4 separate 
experiments. (*P<0.05, **P < 0.01, ***P<0.001 versus ctrl).  
 
 
These data, although not fully convincing, are unable to support TLR4 as the 
receptor for eNAMPT. A number of explanations may be provided for these 
negative findings, including the possibility that eNAMPT binds to TLR4 with 
lower affinity compared to LPS or that it is responsible for the late activation 
of NF-κB. However, our results are largely inconclusive.  
Interestingly, genome-wide gene expression analysis reveals similarities in 
genes up-regulation evoked by eNAMPT and LPS32. Therefore, to shed light 
on this aspect, we moved to ex vivo experiments using mouse peritoneal 
macrophages (PEC), which expressed both TLR4 and MD-2. As expected, the 
treatment of macrophages with LPS (100 ng/ml for 4 hours, Figure 3A) was 
able to increase several pro-inflammatory cytokines (i.e. iNOS, COX-2, 
IL12p40, CXCL9, CXCL10, IFNβ, IL-6, IL-1β, ΤΝF, IL23p19), however 
eNAMPT induced the up-regulation only of CXCL9, CXCL10, IL-6, and IL-
1β (Figure 3B).  
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Figure 3. RT-PCR analysis of M1-polaritazion-associated genes (iNOS, COX-2, IL12p40, 
CXCL9, CXCL10, IFNβ, IL-6, IL-1β, ΤΝF, IL23p19) and M2-polarization-associated genes 
(FIZZ, ArgI, YmI) in peritoneal exudate cells (PECs) isolated from C57BL6 mice and 
stimulated for 4h with LPS (100ng/ml) (A) and eNAMPT (500ng/ml) (B). Representative data 
of 3 separate experiments. 
 
 
 
In conclusion, the experiments conducted in this section are very preliminary 
and inconclusive. They represent a small part of my PhD work, but I believe 
that investigating this aspect based on Garcia’s finding was relevant and 
essential for the objective of my thesis. Unfortunately, the time spent for them 
was insufficient to obtain strong results, but this is still an open project in the 
laboratory of Armando Genazzani. 
 
	 	
Key findings: 
 
- Data on TLR4 and eNAMPT from my work are largely inconclusive; 
- We failed to see an activation by eNAMPT of TLR4 in MD-2 deficient cells 
or a strong activation in Jurkat cells, which express MD-2; 
- We observed a moderate and late increase in p65-phosphorylation in MD-2 
expressing cells; 
- Similarities exist between LPS and eNAMPT in the pattern of up-regulation 
of genes in peritoneal macrophages, but results are not superimposable. 
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UNPUBLISHED RESULTS 
 
Investigation of a putative receptor for extracellular 
Nicotinamide Phosphoribosyltransferase (eNAMPT) using 
fluorescent probes  
 
INTRODUCTION 
The identity of the eNAMPT receptor is still unknown although there is 
sufficient evidence that suggests that a plasma membrane receptor exists and 
mediates at least part of the effects of eNAMPT. We have demonstrated that 
eNAMPT binds to CCR5 acting as natural antagonist, but this interaction is 
unlikely to explain many of the effects observed with eNAMPT. To identify 
other putative eNAMPT receptors, we therefore decided to use a different 
experimental approach. 
In 1970 Lefkowitz RJ et al. first described an innovative assay to study and 
characterize receptor-ligand interactions using radiolabelled proteins1. In 
subsequent years, radioligand binding assays were widely used to discover new 
receptors and/or investigate new ligands. Given that this technique is perceived 
as costly, risky and dangerous to the users, has an environmental impact and 
requires a custom infrastructure, researchers have been encouraged to develop 
ligand-binding assays not based on radioactivity, but rather based on 
fluorescent-labelled ligands. One of the first fluorescent-ligand binding assays 
was developed in 1988 by Yamasaki K et al. They have taken advantage from 
fluorescence probe techniques to discover the IL-6 receptor. In their strategy, 
they coupled FITC to the IL-6 protein and evaluated binding by using FACS 
analysis on COS7 cells transfected with different cDNAs. They observed that 
FITC-IL6 was able to bind on the cell surface of COS7 transfected with 
pBSF2R.236 cDNA plasmid, identifying the coding sequence of the IL-6 
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receptor. In addition, they demonstrated that cells that lacked mRNA for the 
sequence they identified (e.g. Jurkat cells) were unable to bind FITC-IL62.  
In the last years, different types of fluorophores have been developed with 
different spectra of excitation and emission to improve the emission intensity 
and to reduce the quenching phenomena and the effect of temperature, pH and 
ionic strength on fluorescent emission. For example, the Alexa Fluor® 488 
dye, which has the same excitation and emission spectra of fluorescein, is 
brighter and more photostable than fluorescein. In addition, the intensity 
fluorescence of the Alexa Fluor® 488 dye is insensitive to pH between 4 and 
10 as opposed to fluorescein. We decided to develop a fluorescent eNAMPT 
labelled with the Alexa Fluor® 488 dye to investigate new interactors.  
 
MATERIALS AND METHODS 
 
Cell culture 
B16 (murine melanoma) and 4t1 (murine mammary carcinoma) cells were 
cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% 
foetal bovine serum (FBS), 2 mg/ml glutamine, 10 U/ml penicillin and 100 
µg/ml streptomycin (Sigma, St. Louis, MO, USA). Cells were maintained in a 
humidified incubator supplied with 5% CO2/95% air at 37°C.  
 
Recombinant eNAMPT preparation  
Wild-type murine full-length NAMPT (ORF GenBank BC018358) was cloned 
in pET28a (NdeI/EcoRI). Recombinant eNAMPT was expressed in E. Coli 
(ClearColi, BL21 DE3) (inducted with IPTG 0.5 mM for 3 h at 20°C) and 
purified by His-tag affinity chromatography with NiNTA Superlow resin 
(Qiagen).  
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eNAMPT 488 preparation 
eNAMPT was labelled with Alexa Fluor®488 Protein Labelling Kit 
(Molecular Probes) according to manufacture manual. Briefly, 1 mg of 
eNAMPT was incubated with Alexa Fluor®488 for 1 hour at room temperature 
and free dye was removed by column resin. The labelled eNAMPT-488 was 
collected and the concentration and the degree of labelling were controlled 
using a spectrophotometer. 
 
Purification of membrane fraction from tissues of mice 
Heart, lung, brain, kidney, liver, adipose tissue, spleen and bone marrow 
obtained from C57BL/6 mice were weighed and cut with scalpel. Five volumes 
of homogenizer buffer (20 mM Hepes pH 7.2, 0,5 mM EGTA, 0.32 M sucrose, 
1 mM β-mercaptoethanol) were added and tissues were lysate in a potter with 
30 strokes and centrifuged at 600g 10 min at 4°C to remove debris and intact 
cells. The supernatants were collected and centrifuged at 10000g for 10 min at 
4°C, to remove the nuclei. The supernatants were collected and subsequently 
centrifuged at 40000g for 45min at 4°C to obtained membrane fractions. 
Membranes were washed twice and resuspended in homogenizer buffer.  
 
Competitive binding assay  
Spectrophotometer analysis: labelled eNAMPT-488 (5 µg) with or without 
unlabelled eNAMPT (500 µg) was added to 50 or 100 µg of membrane extracts 
in binding buffer (137 mM NaCl, 2.7 mM KCL, 10 mM Na2HPO4, 1.7 mM 
KH2PO4, pH 7.2) and the mixture was incubated for 1h at 4°C on a wheel. 
Then, membranes were washed 3 times with binding buffer and centrifuged at 
20000g 15min 4°C. The pellet was then solubilized in binding buffer and 
transferred in a black plate. Fluorescence was acquired using a Viktor3 plate-
reader. 
SDS-page analysis: labelled eNAMPT-488 (5 µg) with or without unlabelled 
eNAMPT (500 µg) was added to tissue membranes in binding buffer and the 
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mixture was incubated for 1h at 4°C on a wheel. Then, the membranes were 
washed 3 times and centrifuged at 20000g for 15min at 4°C in binding buffer. 
Pellets were then resuspended in 50 µL of binding buffer and loaded on SDS-
page gels. Images were acquired using Chemidoc Biorad with the Alexa Fluor 
488 program. 
 
Pull down with NI-NTA beads and cross-linking 
Recombinant NAMPT (50 µg) was incubated with 100 µL of NI-NTA beads 
for 15 minutes at 4°C. Then, beads were washed 3 times in wash buffer (50 
mM NaH2PO4 pH 7.5, 0.5 M NaCl, 40 mM imidazole) and added to kidney or 
liver membranes (700 µg) for 1h at 4°C. Subsequently, beads were washed 3 
times in wash buffer, and 0.01% of glutaraldehyde was added for 45 min at 
4°C. The reaction was quenched with Tris-HCl (1M, pH 8) and the samples 
were loaded on SDS-page. Proteins were analysed via western blot and/or 
silver stain. The gel bands were analysed by Liquid chromatography–mass 
spectrometry (LC-MS) in collaboration with the Laboratory of Prof. Emilio 
Marengo, University of Piemonte Orientale.  
 
Western blot analysis 
Membranes were lysed in 80 µL in lysis buffer composed of 20 mM HEPES, 
100 mM NaCl, 5 mM EDTA, 1% SDS + Protease & Phosphatase Inhibitor 
Cocktail (Sigma). Protein quantification was performed with BCA Protein 
Assay (Thermo Fisher Scientific, Waltham, MA, USA), and proteins were 
resolved on SDS–PAGE. Densitometry analysis was performed with Quantity 
One program (Bio-Rad, Hemel Hempstead, UK). 
 
FACS analysis 
3 × 105 cells were trypsinised, wash 3 times in cold PBS, and suspended in 
PBS. eNAMPT-488, at different concentrations, was added to cells and 
incubated at 4°C for the indicated time points. Cells were washed 3 times in 
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ice cold PBS and resuspended in FACS Buffer (Hanks' Balanced Salt solution 
HBSS + 0.5% BSA). Samples were analysed using a FACS (BD accuri).   
 
Immunofluorescence 
2 × 104 B16 cells were seeded on a 13mm coverslip. Cells were washed in PBS 
and incubated with 10 µg of eNAMPT-488 in Locke’s solution (134 mM NaCl, 
5mM KCl, 4 mM NaHCO3, 10 mM HEPES, 2.3 mM CaCl2, 1 mM MgCl2, 5 
mM Dextrose, pH 7.4) for 1 hour at 4°C. Then, cells were cross-linked with 
2mM of BS3 (Bissulfosuccinimidyl suberate) for 2h at 4°C, and after 
quenching with Tris-HCl (1M, pH 7.4), cells were washed with PBS. 
Subsequently cells were fixed with PFA 4% for 15 minutes at 4°C and stained 
with DRAQ5 (2.5 µM) for 20 minutes. Then, cells were washed in PBS and 
mounted onto cover slips to be visualized with confocal microscopy (Leica). 
 
Reagents 
Mouse monoclonal antibody anti-NAMPT was purchased from AdipoGen. 
Mouse monoclonal antibody anti-HSP90 and Mouse monoclonal antibody 
anti-CoxIV were purchased from Santa Cruz Biotechnology. Rabbit polyclonal 
anti-H2A was purchased from Abcam. Rabbit polyclonal anti-E-cadherin and 
was purchased from cell signalling. Peroxidase-conjugated secondary 
antibodies were from Biorad. Glutaraldehyde from Sigma, NI-NTA beads were 
purchased from Quiagen. Bissulfosuccinimidyl suberate (BS3) and Pierce™ 
Silver Stain for Mass Spectrometry were purchased from Thermo Fisher 
Scientific. Glutaraldehyde was purchased from sigma. DRAQ5 was purchased 
from Invitrogen™ Life technology. 
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Results 
Starting from the idea of Yamasaki K et al., we decided to generate a 
fluorescent eNAMPT with Alexa Fluor 488 (eNAMPT-488) to evaluate the 
ability of eNAMPT-488 to bind on cell surface. We started from the murine 
melanoma B16 and mammary carcinoma 4T1 cell lines, in which we 
previously demonstrated that the administration of recombinant eNAMPT 
induced an activation of phospho- ERK1/25 and phospho-STAT-3 (not shown).  
As shown in Figure 1A-B, FACS analysis reveals that the incubation of 
eNAMPT-488 (30ng, 500ng and 1 µg) on B16 cells was able to induce a shift 
in positive FL-1 area (indicative of 488 intensity) in a dose-dependent manner. 
The percentage of B16-positive cells was in a range between 5-20%, while in 
4T1 cells the percentage was between 2-5%. Moreover, in 4T1 cells the 
binding of eNAMPT occurs only with very high amounts of eNAMPT-488 
(1µg), suggesting that the expression of the putative receptor in these cells is 
lower than in B16 cells. Anyway, the strong binding of eNAMPT-488 observed 
on B16 cell surface convinced us to investigate more deeply these findings. 
Therefore, we evaluated the localization and the binding intensity of eNAMPT-
488 via confocal microscopy. 
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Figure 1. eNAMPT-488 bind to the cell surface of B16 and 4T1 cells. Representative flow 
cytometry analysis of B16 cells (A) and 4T1 cells (B) incubated with eNAMPT-488 (30ng, 
500ng, 1 µg) for 60 minutes and analysed using FACS BD accuri. (C) Confocal images of B16 
cells treated with eNAMPT-488 (10 µg, green) for 60 minutes, stained with DRAQ5 (nuclear 
marker, blue). Representative images of 3 determinations of 3 separate experimental days. 
 
B16 cells were treated with 10 µg of eNAMPT-488 and crossed-linked with 
BS3, in order to avoid a possible dissociation of the protein-receptor binding 
during the different steps of the protocol. Specifically, the BS3 cross-linker is 
membrane-impermeable, helping the study of cell surface interactions, and has 
a space arm of 11.4 angstrom, that reduces the unspecific cross-linking. The 
cells were then fixed and analysed by confocal microscopy. As shown in Figure 
1C, eNAMPT-488 was linked to the cell surface membrane of B16 cells, 
confirming the data obtained by flow cytometry.  
These data confirm our hypothesis that eNAMPT is able to bind a putative 
receptor and that the receptor is present in melanoma cells. 
To better characterize these evidences and to improve the probabilities to 
obtain a functional competitive binding assay by increasing the percentage of 
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positive cells linked to eNAMPT-488, we moved to membranes obtained from 
whole tissues.  
We generated membrane fractions from heart, lung, brain, kidney, liver, 
adipose tissue, spleen and bone marrow of C57BL/6 mice. To confirm the 
purity of the membranes in the isolation process, we performed a western blot 
analysis of membrane fractions for E-cadherin and Cox-IV (membrane 
markers), for HSP90 (cytosolic marker) and H2A (nuclear marker) (Figure 2).  
 
 
 
Figure 2. Isolation of tissue membranes. Western blot analysis of HSP90, H2A, E-cadherin 
and CoxIV levels in different tissues. Representative data of tissue membrane preparation. 
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Figure 3. eNAMPT-488 binds to tissue membranes. (A) Tissue membranes (50, 100 µg) 
were incubated with eNAMPT-488 (5 µg) in binding buffer for 1 hour at 4°C. Then, the 
fluorescence was acquired using Victor3. Histograms of relative fluorescent intensity as mean 
± S.E.M. of 5-6 independent experiments. (B) Tissue membranes (100 µg) were incubated 
with eNAMPT-488 (5 µg) in presence or absence of unlabelled eNAMPT (500 µg) in binding 
buffer for 1 hour at 4°C. Histograms of relative fluorescent intensity as mean ± S.E.M. of 5-7 
independent experiments. (C) Histograms represent the fluorescence intensity of eNAMPT-
488 (5 µg) with or without eNAMPT (500 µg) after 1 hour at 4°C of incubation in absence of 
tissue membranes. Histograms of relative fluorescent intensity as mean ± S.E.M. of 5 
independent experiments. 
 
To evaluate whether labelled eNAMPT-488 was able to bind to tissue 
membranes, we performed a fluorescent binding assay in the presence or 
absence of an excess amount of unlabelled eNAMPT, and the fluorescent 
intensity was acquired using Victor3 spectrophotometer.  
As shown in Figure 3A, eNAMPT-488 (5 µg) was able to bind to all tissues 
tested. In the competitive binding assay, in which unlabelled eNAMPT (500 
µg) was added together with labelled eNAMPT (5 µg), the binding of 
eNAMPT-488 was inhibited significantly only in kidney (Figure 3B). 
Unfortunately, in some tissues we observed an increase of fluorescent intensity 
when labelled and unlabelled eNAMPT were incubated together (e.g. liver). 
Overall, while most of the data suggested that the binding of eNAMPT on 
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membranes occurred, the inability of unlabelled eNAMPT to displace the 
fluorescence raised doubts on the phenomenon.  
Thus, we proceeded in verifying whether an interaction occurred between 
labelled and unlabelled eNAMPT in the absence of membranes. To our 
surprise, we observed that the fluorescence intensity was significantly higher 
in the presence of unlabelled eNAMPT (Figure 3C). Moreover, we performed 
a repeated acquisition of fluorescence intensity at different time points and the 
fluorescence intensity changed over time, resulting in a high variability (not 
shown).  The above data were drawback, as they suggest that standard 
displacement protocols, usually employed in binding assay, could not be 
performed. The reason is unclear and might be attributed to a change in protein 
folding as well as to the formation of labelled-unlabelled dimers. In either case, 
fluorescence cannot be reputed linear with membrane binding, a pre-requisite 
for quantitative approaches.  
We therefore decided to change the conditions of the binding experiments, 
moving to a static system, i.e. SDS-Page gels, in order to avoid possible 
dynamic conformational changes or protein-protein interactions that might 
compromise fluorescence linearity. We decided to start this novel approach 
analysing the binding in two organs that, in the preliminary experiments 
yielded the highest signal, kidney and liver. Briefly, eNAMPT-488 with or 
without the unlabelled eNAMPT was incubated with membrane fractions and 
samples were then loaded into a SDS-page gel to resolve the proteins. The 
fluorescence of the bands on the gel was then analysed via the Chemidoc 
equipment.  
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Figure 4. Competitive binding assay. (A) eNAMPT-488 (500 ng) was incubated in presence 
or absence of unlabelled eNAMPT (50 µg) for 1 hour at 4°C. Then samples were resolved in 
SDS-page and fluorescence intensity was acquired using Chemidoc (Bio-Rad) with Alexa 
fluor 488 program. Representative SDS-page gel (left panel) and histogram (right panel) of 
eNAMPT-488 fluorescence intensity. (B) Liver and kidney tissue membranes (100 µg) were 
pre-incubated or co-incubated with unlabelled eNAMPT (500 µg) in presence or absence of 
eNAMPT-488 (5 µg) in binding buffer for 1 hour at 4°C. Representative SDS-page gel (left 
panel) and histogram (right panel) of eNAMPT-488 fluorescence intensity. (5 independent 
experiments) **P < 0.01, ***P<0.001 versus control.  
 
As shown in Figure 4A, a fluorescent band corresponding to the correct 
molecular weight of eNAMPT was evident in this procedure. Pre-incubation 
with an excess of unlabelled eNAMPT resulted in both tissues in a reduction 
of the fluorescence intensity, which was significant in both cases as determined 
by densitometry. Both co- and pre- incubation resulted in a reduction of the 
displacement, as would be expected (Figure 4B).  
These new evidences convinced us of the existence of a competitive binding 
for eNAMPT in kidney and liver membranes, which could be translated in a 
concrete possibility of the presence of an eNAMPT receptor in these 
preparations. We next decided to identify its nature through the pull-down of 
the complex and subsequent analysis of LC-MS.  
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Towards this aim, we took advantage of the histidine tag of recombinant 
eNAMPT, which is specifically recognized by NI-NTA beads. Briefly, 
eNAMPT was incubated with NI-NTA beads, added to tissue membranes and 
cross-linked with glutaraldehyde. Samples were then loaded in SDS-page gel 
and developed with antibody against NAMPT. Subsequently, the bands of 
interest were analysed by LC-MS. 
As shown in Figure 5A, we were able to recognise the monomeric and dimeric 
forms of cross-linked eNAMPT alone at expected molecular weights (50 kDa 
for the monomer and 110 kDa for the dimer). When eNAMPT was cross-linked 
with membranes, we observed the appearance of bands with molecular weight 
higher than 110 kDa (Figure 5A, band B). In contrast to the above bands, we 
are unable to determine whether these bands contain the receptor or whether 
sufficient amounts are present to be detectable by LC-MS. 
Figure 5. Pull down assay of eNAMPT interactors from membranes. eNAMPT (50 µg) 
was incubated with NI-NTA beads in presence or absence of liver and kidney tissue 
membranes (700 µg) in binding buffer for 1 hour at 4°C. Then samples were cross-link and 
the proteins were resolved by SDS-Page. Representative silver stain (A) and western blot (B) 
of eNAMPT alone and in presence or absence of membranes. 
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We performed LC-MS analysis in collaboration with Dr. Marcello Manfredi 
(University of Piemonte Orientale, Alessandria) of the bands named A, B, C, 
D and E in Figure 5. D and E bands were analysed as controls to verify the 
presence of eNAMPT in the samples. In band B, LC-MS identified two 
interested proteins such as glyceraldehyde-3-phosphate dehydrogenase, 
sodium/potassium-transporting ATPase subunit alpha 1 and 3 and obviously 
eNAMPT (Table 1). Table 1 shows the proteins identified by this technique. It 
must be noted that LC-MS also revealed in band B cytosolic and nuclear 
proteins, such histones, nuclear receptor coactivator 2, calmodulin and actin, 
suggesting that the membrane preparations were contaminated with cytosolic 
and nuclear proteins. 
Table 1. eNAMPT interactors identified through LC-MS analysis 
 
protein	description prot_score prot_mass N°	peptide
10853|H2B1F_MOUSE	Histone	H2B	 411 13928 8
Q6GSS7|H2A2A_MOUSE	Histone	H2A	 168 14087 2
Q99KQ4|NAMPT	MOUSE	 121 55698 3
P16858|Glyceraldehyde-3-phosphate	dehydrogenase	 55 36072 3
Q6PIC6|Na+/k+	-transporting	ATPase	subunit	alpha-3	 41 113045 2
Q8VDN2|Na+/k+	-transporting	ATPase	subunit	alpha-1	 24 114221 2
Q61026|Nuclear	receptor	coactivator	2	 22 159221 1
Q99P72-1|Isoform	3	of	Reticulon-4	 21 22452 1
protein	description prot_score prot_mass N°	peptide
P36369|K1B26_MOUSE	Kallikrein	1-related	peptidase	 142 224807 3
Q3TD16|K226L_MOUSE	Uncharacterized	protein	 68 1246366 6
Q3UH68-2|LIMC1_MOUSE	Isoform	2	of	LIM	 14 101706 3
protein	description prot_score prot_mass N°	peptide
sp|Q99KQ4|NAMPT_MOUSE	 229 55698 2
Q61846|MELK_MOUSE	Maternal	embryonic 29 73709 1
Q3UV17|K22O_MOUSE	Keratin,	type	II	cytoskeletal 27 63319 1
protein	description prot_score prot_mass N°	peptide
sp|Q99KQ4|NAMPT_MOUSE 76 55698 2
sp|Q8BJH1-2|ZC21A_MOUSE 40 31891 1
sp|Q61846|MELK_MOUSE 27 73709 1
Band	C
Band	D
Band	E
Band	B
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We also performed a further analysis with StavroX program, which is 
specifically programmed for Cross Linking-Mass Spectrometry Analysis. 
Indeed, cross-linking creates an analysis bias by which cross-linked proteins 
would not be recognized by expected molecular weights. The analysis with 
StavroX of band B, revealed that eNAMPT was in complex with 
glyceraldehyde-3-phosphate dehydrogenase, sodium/potassium-transporting 
ATPase subunit alpha 1 and 3 and with the same eNAMPT with a significance 
<0.05 compared to the internal control of decoy analysis. The program also 
suggested a putative sequence of interaction of eNAMPT with glyceraldehyde-
3-phosphate dehydrogenase and sodium/potassium-transporting ATPase 
(Table 2).  
 
Table 2. Peptides corresponding to sequence of interactions identified using StavroX tool. 
 
Score Peptide	1 Protein	1 Peptide2 Protein	2
105 [LNKYLK] Q99KQ4|NAMPT_MOUSE [TGVFTTMEKAGAHLK] P16858|G3P_MOUSE
105 [RKNBLVK] ATPase	subunit	alpha-1	and	alpha-3 [NKILIFGL] ATPase	subunit	alpha-1	and	alpha-3
102 [SSKIM] ATPase	subunit	alpha-1	andalpha-3 [VLDILGKKF] Q99KQ4|NAMPT_MOUSE
102 [ILLQGK] ATPase	subunit	alpha-3 [VLDILGK] Q99KQ4|NAMPT_MOUSE
102 [GKVVT] Q99KQ4|NAMPT_MOUSE [TVLKVLDILGK] Q99KQ4|NAMPT_MOUSE
102 [NBSFK] Q99KQ4|NAMPT_MOUSE [GIALIKK] Q99KQ4|NAMPT_MOUSE
101 [VLDILGK] Q99KQ4|NAMPT_MOUSE [QPRNPKT] ATPase	subunit	alpha-1
100 [YLKGKV] Q99KQ4|NAMPT_MOUSE [LRMYPLK] ATPase	subunit	alpha-1	and	alpha-3
100 [SILLHGK] ATPase	subunit	alpha-1 [AKRMARK] ATPase	subunit	alpha-1	and	alpha-3
99 [KNGKVTK] Q99KQ4|NAMPT_MOUSE [TVKAENGKLVINGK] P16858|G3P_MOUSE
99 [KEVAM] ATPase	subunit	alpha-3 [FNSTNK] ATPase	subunit	alpha-1	and	alpha-3
97 [SGTSFDK] ATPase	subunit	alpha-3 [SEHGDKKGKK] ATPase	subunit	alpha-1
97 [FEBREK] Q99KQ4|NAMPT_MOUSE [ASAHLVNFK] Q99KQ4|NAMPT_MOUSE
97 [NGEKmSIN] ATPase	subunit	alpha-1 [LMRERNK] ATPase	subunit	alpha-3
96 [KTENS] Q99KQ4|NAMPT_MOUSE [VKFBR] ATPase	subunit	alpha-1	and		alpha-3
96 [ADPNK] Q99KQ4|NAMPT_MOUSE [YDNSLKIVSNAS] P16858|G3P_MOUSE
96 [YYGTK] Q99KQ4|NAMPT_MOUSE [YDNSLKIVSNA] P16858|G3P_MOUSE
96 [KYYGT] Q99KQ4|NAMPT_MOUSE [YDNSLKIVSNA] P16858|G3P_MOUSE
Analisys	with	StavroX
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Key finding: 
• The fluorescence binding assays is an efficient technique to track 
membrane proteins that bind to eNAMPT; 
• While artefacts may occur when determining binding in cells via 
spectrophotometer, SDS-page appears to be effective. This technique 
must therefore be useful if a protein purification strategy is sought to 
identify the eNAMPT receptor or to confirm the identity of the 
receptor; 
• Cross-linked fluorescent eNAMPT coupled with LC-MS allows for the 
identification of a number of eNAMPT binding proteins, some of which 
have been validated via other means (see discussion). 
 
 
References 
1.	 Lefkowitz, R.J., Roth, J. & Pastan, I. Radioreceptor assay of 
adrenocorticotropic hormone: new approach to assay of polypeptide 
hormones in plasma. Science 170, 633-635 (1970). 
2. Yamasaki, K. et al. Cloning and expression of the human interleukin-6 
(BSF-2/IFN beta 2) receptor. Science 241, 825-828 (1988). 
3. Breen, C.J., Raverdeau, M. & Voorheis, H.P. Development of a 
quantitative fluorescence-based ligand-binding assay. Sci Rep 6, 25769 
(2016). 
4. Chen, H., Ahsan, S.S., Santiago-Berrios, M.B., Abruna, H.D. & Webb, 
W.W. Mechanisms of quenching of Alexa fluorophores by natural 
amino acids. J Am Chem Soc 132, 7244-7245 (2010). 
5. Grolla, A.A. et al. Nicotinamide phosphoribosyltransferase 
(NAMPT/PBEF/visfatin) is a tumoural cytokine released from 
melanoma. Pigment cell & melanoma research 28, 718-729 (2015). 
 
 
 
 
	 108	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 109	
 
 
 
Chapter 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 110	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 111	
Discussion 
In 1966, Dietrich et al. reported for the first time the enzymatic activity of 
nicotinamide phosphoribosyltransferase (NAMPT), which catalyses the 
formation of nicotinamide mononucleotide (NMN) starting from nicotinamide 
(NAM), 5-phosphoribosylpyrophosphate (PRPP) and adenosine triphosphate 
(ATP)1. Nowadays, NAMPT is considered an important regulatory enzyme 
since it is the rate-limiting enzyme in the nicotinamide adenine dinucleotide 
(NAD) salvage-pathway in mammals2.  
In 1994, Samal et al. identified NAMPT as a secreted protein that enhanced 
the proliferation and differentiation of lymphocytes B3. From that time on, the 
extracellular form of NAMPT (eNAMPT) was classified as a cytokine, a factor 
released from cells with paracrine and autocrine effects. Large amount of data 
have demonstrated that eNAMPT has the ability to activate intracellular 
pathways such as NF-κB, Akt, p38 and MAPK, and leads to the control of 
angiogenesis, cellular proliferation, cell differentiation and migration4-6.  
To date, the information available in the literature reveal that the extracellular 
form of NAMPT has the same sequence and structure of the intracellular form, 
maintaining its ability to dimerize7. This insinuates the doubt if its function in 
the extracellular space is due to its ability to form NMN or to the binding to a 
plasma membrane receptor. Some evidences, even if not fully convincing, on 
the identity of eNAMPT receptor are present in literature.  After the retraction 
by Fukuhara of the identification of the insulin receptor as a candidate8, 9, other 
groups started to tackle the issue. In 2012, Van den Bergh et al. demonstrated 
that eNAMPT binds to CCR5 through the technique of Surface Plasmon 
Resonance10, however they did not characterize the biological role of this 
interaction.  
I decided to start from this evidence to develop my PhD project: discover of 
the receptor of eNAMPT. I started from the validation of Van den Bergh’s 
evidence at first by verifying the interaction between eNAMPT and CCR5. The 
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choice to concentrate on CCR5 was mainly due to the fact that the report on 
TLR4 had not been released at the time. 
Initially, I generated an experimental model by over-expressing murine-CCR5 
in HeLa cells in which perform most of the experiments. Through a 
competitive binding assay in which the pre-treatment of the cells with 
recombinant eNAMPT led to a reduction of the binding of the natural ligand 
RANTES to CCR5 receptors, I confirmed effectively an interaction between 
NAMPT and CCR5. Then, I moved to characterize the biological role of this 
interaction. It is known that CCR5 triggers the activation and consequent 
phosphorylation of ERK and the efflux of calcium from endoplasmic 
reticulum. However, in our hands, eNAMPT, tested at different concentrations, 
was not able to induce neither ERK activation nor calcium efflux in HeLa 
CCR5 cells, suggesting that eNAMPT was not behaving as an agonist on this 
receptor. Surprisingly, the pre-incubation with high doses of recombinant 
eNAMPT was able to inhibit the RANTES-mediated calcium transients in 
HeLa-CCR5 cells.  
Coming back on Van den Bergh’s report, they showed that NAMPT was able, 
similar to the CCR5 antagonist maraviroc, to reduce HIV R5 strand (which use 
CCR5 as a co-receptor) infection in macrophages, on the contrary it was not 
able to reduce HIV X4 strand infection (which use CXCR4 as a co-receptor)10. 
Indeed, I started to think that eNAMPT might be considered an antagonist of 
this receptor, binding to it to interfere with the RANTES stimulus.  
Maraviroc is a well-known competitive antagonist of CCR5. This molecule has 
antiretroviral properties and it is also classified as an entry inhibitor and used 
in the treatment of HIV positive patients11-14.  
I then decided to compare the effects of maraviroc to eNAMPT on CCR5-
mediated phenomena.  Effectively, the pre-treatment of eNAMPT was able to 
reduce RANTES-mediated calcium signalling in the same manner of 
maraviroc. In support of this, eNAMPT was not able to internalize the receptor, 
phenomenon that occurs only for CCR5 agonists12.  
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This antagonistic activity seemed to be specific for RANTES-mediated CCR5 
activation. In fact, ATP-induced calcium transients and carbachol-induced 
calcium transients were not affected by eNAMPT treatment, demonstrating 
that it was not a general action on calcium stores, but a specific activity on 
CCR5. 
It is well known that RANTES treatment induces migration and chemotaxis in 
a calcium-dependent manner. Cell migration requires local calcium pulses to 
activate myosin and to modulate focal adhesions. In this context, our data 
demonstrated, once again, that eNAMPT was interfering with CCR5 by 
reducing RANTES-mediated migration in the same manner of maraviroc.  We 
performed these experiments on B16 melanoma cells as HeLa cells have a 
reduced tendency to migrate. To corroborate these data, we confirmed the 
antagonistic effects of eNAMPT on RANTES-mediated calcium signalling 
even in B16 cells. 
All together these evidences demonstrate that eNAMPT can act as an 
antagonist against CCR5. 
A concrete example of this antagonistic effect on CCR5 signalling is the 
chemokine monocyte chemotactic protein-3 (MCP-3), also named CCL7. 
MCP-3 is the unique endogenous antagonist proposed for CCR515. It abolishes 
CCR5-dependent calcium signalling and cell migration, while at lower doses 
it is an agonist of CCR1, CCR2 and CCR316.  Indeed, it has been reported that 
the chemokines MCP-1, MCP-2, MCP-3 and RANTES induced a migration 
response with bimodal concentration dependence, with different efficacy and 
curve trend17.  
Therefore, my hypothesis is that eNAMPT might have the same behaviour of 
MCP-3 protein: it may be an antagonist of CCR5 receptor at a certain dose and 
in a specific type of cell, while it may activate other pathways at similar or 
different concentrations or in a different context (Figure 1A).  
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In support of my hypothesis, I performed a preliminary in silico analysis using 
PyMol and Uniprot software, which revealed a common structure 
conformation and conserved sequencing between eNAMPT and MCP-3. 
As shown in Figure 1B, the Pymol analysis of the NAMPT (cyano) and MCP-
3 (orange) structures showed a strong homology. Specifically, MCP-3 random 
coil (highlighted by the red square), which is used by the protein to bind to 
CCR5, is superimposable with a portion of the NAMPT structure (amino acids 
420-430). Moreover, the chemical-physical features of the amino acids of this 
portion are comparable to the steric hindrance of MCP-3 in the same region.  
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Figure 1. A) Scheme of RANTES, MCP-3 and eNAMPT signalling; B) PyMol analysis of 
alignment of eNAMPT (ciano) and MCP-3 (orange) sequences. Red square indicates the 
random coil in common between NAMPT and MCP-3, which leads to bind to CCR5. 
 
Thus, our experimental data and our assumption derived from the in silico 
model can support the role eNAMPT as antagonist of CCR5 and its similarity 
with the natural antagonist MCP-3, both in the structure and in the functions. 
 
During the second year of PhD, an innovative paper was published by Camp 
et al. They reported that eNAMPT binds to and activates Toll-like receptor 4 
(TLR4), inducing NF-κB activation in human lung endothelium. Through the 
antibodies against eNAMPT and TLR4, and the use of TLR4 KO mice, they 
validated this hypothesis18. Of course, I decided to devote part of my 
experiments to validate their hypothesis also in my models. 
Taken together, my results only partially recapitulate the evidence of Camp et 
al. In my hands, we failed to observe an activation of TLR4 in MD-2 deficient 
cells, maybe suggesting that eNAMPT requires MD-2 for TLR4 activation, 
contrarily to what affirmed. Yet, eNAMPT seems to bind to TLR4 because it 
induces a mild and late increase in p65-phosphorylation in MD-2 expressing 
cells (Jurkat). Moreover, eNAMPT up-regulated four genes (CXCL9, 
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CXCL10, IL-6, and IL-1β) involved in TLR4 signalling in ex vivo peritoneal 
macrophages.  
Therefore, this evidence on TLR4 brings further support to the idea that more 
than one receptor may be recognized by eNAMPT, yielding therefore a 
complex pattern. This is further supported by the notion that NF-κB is not the 
only intracellular pathway activated by eNAMPT from literature4-6, 19. 
Moreover, our results were not able to convince us that eNAMPT actions were 
fully comparable to those of LPS, even if we recognize that many other 
experiments should be carried to fully elucidate this issue.  
A crucial element regarding the experiments with TLR4 is the absolute 
necessity to avoid any endotoxin contamination in eNAMPT preparations. We 
have paid incredible attention to ensure that recombinant proteins (in our case 
eNAMPT) used for cell treatment and all the reagents and tools used in the 
experiments were completely endotoxin-free. For example, our eNAMPT were 
prepared from ClearColi BL21 (DE3) kit, in which the bacterial strain has been 
modified to express an LPS modified form not recognised by the receptor and 
the preparations were subjected to the LAL test. Our eNAMPT was 
comparable to most commercial available recombinant proteins, which puts us 
in a situation at par with others, but does not give a 100% guarantee of totally 
LPS-free preparations. Only the use of samples from the TLR4 KO mouse 
model could inform us without further doubt that the gene expression changes 
peritoneal exudates can be attributed to the activation of TLR4. 
Taken together, the evidences that I obtained regarding CCR5 and TLR4 as 
eNAMPT receptor candidates, are not fully convincing and conclusive. At 
present, the working hypothesis is that eNAMPT antagonizes CCR5, mildly 
activates the TLR4 and that further receptors may be involved in explaining 
the full spectrum of effects. In this setting, there is room for actions attributable 
also to its enzymatic activity and to NMN. 
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In this scenario, I decided to pursue a fishing strategy to identify further 
receptors. As other researchers have attempted to identify the eNAMPT 
receptor by using the yeast two-hybrid technique and by screening cDNA 
libraries without being able to achieve appreciable results, it persuaded us to 
move in a different direction4. 
I set up and validated a method to identify new membrane interactors of 
eNAMPT by using fluorescent probes. Our idea arises from the evidences of 
Yamasaki K et al., which discovered the IL-6 receptor using a fluorescence IL-
6 on COS7 transfect cells20. We paralleled their experiments by generating a 
labelled eNAMPT-488 to analyse its binding to the membranes.  
Despite initial problems with artefacts in our model, we demonstrated an 
effective binding of eNAMPT to the membranes of both B16 melanoma and 
4T1 mammary carcinoma cells, both with FACS analysis and confocal 
imaging. 
To improve the quality of our results and allow this technique to support future 
identifications, we required an increased amount of protein coupled with 
homogeneity of our preparations, and for this we moved to mouse tissues. A 
competitive binding assay, in which unlabelled NAMPT was used to compete 
with the binding of eNAMPT-488, revealed that in kidney and liver 
membranes a partial displacement occurred, indicating an effective binding to 
a competitive site. 
The following step was to pull-down the interactors present in kidney and liver 
preparations and to identify them through LC-MS analysis. For this, we took 
advantage from the cross-linking technique, via a BS3 linker, which allows to 
fix and stabilize the interaction between proteins and to improve the quality 
and accuracy of the results.  
Our very preliminary data indicate two possible interesting proteins: GAPDH 
(Glyceraldehyde-3-phosphate dehydrogenase) and Na+/K+ ATPase subunit 1 
and 3 (Sodium/potassium-transporting ATPase).  
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While the presence of GAPDH might at first appear to be an artefact, a member 
of my lab (Ambra Grolla; personal communication) has strong evidence that 
this interaction occurs and may be relevant both in a physiological and 
pathological perspective. This provides therefore reassurance on the validation 
of the method. 
On the other hand, despite the fact that GAPDH has been demonstrated to be 
also at plasma membrane21, its presence in our preparations may be translated 
in a partial contamination with the cytosolic fraction and this may mean that 
further characterizations of the membrane preparations may be required in the 
future. 
Since 1994, when eNAMPT was described for the first time as a cytokine, no 
one has reported convincing evidence on the identity of its receptor(s)3. A 
possibility to explain the difficulty that has challenged researchers and that has 
probably been over-looked deals with the large variability of eNAMPT 
preparations that have been used. Indeed, most results in the literature have 
been recombinant NAMPT produced in bacteria, which might not be 
superimposable, for post-translational modifications, to mammalian eNAMPT. 
Members of my lab are at present tackling this issue (Cristina Travelli, Michele 
Bianchi, personal communication) and are finding striking differences between 
eukaryotic and prokaryotic recombinant eNAMPT preparations. Future studies 
should possibly use recombinant protein obtained from HEK293T or CHO 
cells, which may be more reliable and relevant. Such a drawback, which 
somehow may explain part of my negative results, is shared by the entire 
literature: even Camp et al., in the material and methods section of the 
manuscript reporting the TLR4 interaction, reported “Commercially available 
recombinant NAMPT/PBEF exhibits batch/lot variability on NF-κB 
signalling, possibly via post-translational modifications or loss of 
bioactivity”18.  
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In conclusion, the scheme of Figure 2 summarizes all the evidences that I 
obtained during my PhD on eNAMPT, that has allowed me to define eNAMPT 
as an antagonist of CCR5 and to hypothesize that this protein may be a 
promiscuous ligand for multiple receptors.  
 
 
Figure 2. Summarizing scheme of eNAMPT findings 
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